Compare,PMID,Parameter,Sentece,Title,Type,URL,Units,Value,id,Drugbank_id,Name
,2206815,maximum plasma concentration,The tablets showed evidence of controlled-release properties: the maximum plasma concentration (10.8 +/- 2.5 mg/l) was obtained after 3.4 +/- 1.6 hours.,Pharmacokinetic study of controlled-release choline theophyllinate in elderly patients. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2206815/),[mg] / [l],10.8,113,DB00122,Choline
,2206815,trough level,The mean trough level was 6.6 +/- 1.5 mg/l and the difference between the peak and trough levels was 4.1 +/- 1.2 mg/l.,Pharmacokinetic study of controlled-release choline theophyllinate in elderly patients. ,Ctrough-Q37,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2206815/),[mg] / [l],6.6,114,DB00122,Choline
,2206815,steady-state plasma theophylline concentration,The mean steady-state plasma theophylline concentration was 8.5 +/- 2.2 mg/l.,Pharmacokinetic study of controlled-release choline theophyllinate in elderly patients. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2206815/),[mg] / [l],8.5,115,DB00122,Choline
,2206815,elimination half-life,The mean elimination half-life was 14 +/- 7 hours.,Pharmacokinetic study of controlled-release choline theophyllinate in elderly patients. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/2206815/),h,14,116,DB00122,Choline
,2206815,volume of distribution,The mean volume of distribution was 0.8 +/- 0.4 l/kg.,Pharmacokinetic study of controlled-release choline theophyllinate in elderly patients. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2206815/),[l] / [kg],0.8,117,DB00122,Choline
,2206815,total body clearance,The mean total body clearance was 0.05 +/- 1/h/kg.,Pharmacokinetic study of controlled-release choline theophyllinate in elderly patients. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2206815/),1/[h·kg],0.05,118,DB00122,Choline
,2248845,steady state plasma concentration,Atracurium was infused for the first 1 h to maintain a target steady state plasma concentration of 1.0 microgram ml-1.,Pharmacokinetics of atracurium during continuous infusion. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2248845/),[μg] / [ml],1.0,1378,DB00122,Choline
,2248845,clearances,"The clearances of atracurium, estimated by the constant infusion rate required to maintain the steady state plasma concentration, at 50-60 min and during estimation of Cpss90 were 3.8 (1.0) and 3.9 (1.1) ml kg-1 min-1 (ns), respectively.",Pharmacokinetics of atracurium during continuous infusion. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2248845/),[ml] / [kg·min],3.8,1379,DB00122,Choline
,2248845,Cpss90,"The clearances of atracurium, estimated by the constant infusion rate required to maintain the steady state plasma concentration, at 50-60 min and during estimation of Cpss90 were 3.8 (1.0) and 3.9 (1.1) ml kg-1 min-1 (ns), respectively.",Pharmacokinetics of atracurium during continuous infusion. ,Css-Q34,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2248845/),[ml] / [kg·min],3.8,1380,DB00122,Choline
,2248845,Cpss90,"The clearances of atracurium, estimated by the constant infusion rate required to maintain the steady state plasma concentration, at 50-60 min and during estimation of Cpss90 were 3.8 (1.0) and 3.9 (1.1) ml kg-1 min-1 (ns), respectively.",Pharmacokinetics of atracurium during continuous infusion. ,Css-Q34,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2248845/),[ml] / [kg·min],3.9,1381,DB00122,Choline
,2248845,volume of distribution at steady state,"The volume of distribution at steady state of atracurium after 1 h of infusion, calculated using the clearance and the area under the plasma concentration-time curve to 1 h, was 130 (50) ml kg-1.",Pharmacokinetics of atracurium during continuous infusion. ,Vss-Q65,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2248845/),[ml] / [kg],130,1382,DB00122,Choline
,2248845,area under the plasma concentration-time curve to 1 h,"The volume of distribution at steady state of atracurium after 1 h of infusion, calculated using the clearance and the area under the plasma concentration-time curve to 1 h, was 130 (50) ml kg-1.",Pharmacokinetics of atracurium during continuous infusion. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2248845/),[ml] / [kg],130,1383,DB00122,Choline
,11520209,IC(50),"A selected compound UR-12715 (49c) showed an IC(50) of 8 nM in the in vitro PAF-induced aggregation assay, and an ID(50) of 29 microg/kg in the in vivo PAF-induced hypotension test in normotensive rats.",Novel azo derivatives as prodrugs of 5-aminosalicylic acid and amino derivatives with potent platelet activating factor antagonist activity. ,IC50-Q10,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11520209/),nM,8,12656,DB00122,Choline
,11520209,ID(50),"A selected compound UR-12715 (49c) showed an IC(50) of 8 nM in the in vitro PAF-induced aggregation assay, and an ID(50) of 29 microg/kg in the in vivo PAF-induced hypotension test in normotensive rats.",Novel azo derivatives as prodrugs of 5-aminosalicylic acid and amino derivatives with potent platelet activating factor antagonist activity. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11520209/),[μg] / [kg],29,12657,DB00122,Choline
,33677546,Cmax,"Median (IQR) amphotericin B Cmax on Day 1 was 24.6 μg/mL (17.0-34.9 μg/mL), which increased to 40.9 (25.4-53.1) and 33.2 (29.0-46.6) μg/mL on the last day of combination and monotherapy, respectively.",Low antileishmanial drug exposure in HIV-positive visceral leishmaniasis patients on antiretrovirals: an Ethiopian cohort study. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/33677546/),[μg] / [ml],24.6,13197,DB00122,Choline
,33677546,Cmax,"Median (IQR) amphotericin B Cmax on Day 1 was 24.6 μg/mL (17.0-34.9 μg/mL), which increased to 40.9 (25.4-53.1) and 33.2 (29.0-46.6) μg/mL on the last day of combination and monotherapy, respectively.",Low antileishmanial drug exposure in HIV-positive visceral leishmaniasis patients on antiretrovirals: an Ethiopian cohort study. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/33677546/),[μg] / [ml],40.9,13198,DB00122,Choline
,33677546,Cmax,"Median (IQR) amphotericin B Cmax on Day 1 was 24.6 μg/mL (17.0-34.9 μg/mL), which increased to 40.9 (25.4-53.1) and 33.2 (29.0-46.6) μg/mL on the last day of combination and monotherapy, respectively.",Low antileishmanial drug exposure in HIV-positive visceral leishmaniasis patients on antiretrovirals: an Ethiopian cohort study. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/33677546/),[μg] / [ml],33.2,13199,DB00122,Choline
,33677546,concentration,Day 28 miltefosine concentration was 18.7 (15.4-22.5) μg/mL.,Low antileishmanial drug exposure in HIV-positive visceral leishmaniasis patients on antiretrovirals: an Ethiopian cohort study. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/33677546/),,18.7,13200,DB00122,Choline
below,33677546,Cmin,"ARV concentrations were generally stable during antileishmanial treatment, although efavirenz Cmin was below the 1 μg/mL therapeutic target for many patients.",Low antileishmanial drug exposure in HIV-positive visceral leishmaniasis patients on antiretrovirals: an Ethiopian cohort study. ,Cmin-Q36,[Article Link](https://pubmed.ncbi.nlm.nih.gov/33677546/),[μg] / [ml],1,13201,DB00122,Choline
,31542713,EC50,"Compound 19, 2-(benzo[b]thiophen-3-yl)-3-hydroxy-6-methoxy-4H-chromen-4-one, exhibited a broad-spectrum activity against Leishmania spp. (EC50 1.9 μM for Leishmania infantum, 3.4 μM for L. donovani, 6.7 μM for L. major), Trypanosoma cruzi (EC50 7.5 μM) and T. brucei (EC50 0.8 μM).","Discovery of a benzothiophene-flavonol halting miltefosine and antimonial drug resistance in Leishmania parasites through the application of medicinal chemistry, screening and genomics. ",EC50-Q16,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31542713/),μM,1.9,13514,DB00122,Choline
,31542713,EC50,"Compound 19, 2-(benzo[b]thiophen-3-yl)-3-hydroxy-6-methoxy-4H-chromen-4-one, exhibited a broad-spectrum activity against Leishmania spp. (EC50 1.9 μM for Leishmania infantum, 3.4 μM for L. donovani, 6.7 μM for L. major), Trypanosoma cruzi (EC50 7.5 μM) and T. brucei (EC50 0.8 μM).","Discovery of a benzothiophene-flavonol halting miltefosine and antimonial drug resistance in Leishmania parasites through the application of medicinal chemistry, screening and genomics. ",EC50-Q16,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31542713/),μM,3.4,13515,DB00122,Choline
,31542713,EC50,"Compound 19, 2-(benzo[b]thiophen-3-yl)-3-hydroxy-6-methoxy-4H-chromen-4-one, exhibited a broad-spectrum activity against Leishmania spp. (EC50 1.9 μM for Leishmania infantum, 3.4 μM for L. donovani, 6.7 μM for L. major), Trypanosoma cruzi (EC50 7.5 μM) and T. brucei (EC50 0.8 μM).","Discovery of a benzothiophene-flavonol halting miltefosine and antimonial drug resistance in Leishmania parasites through the application of medicinal chemistry, screening and genomics. ",EC50-Q16,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31542713/),μM,6.7,13516,DB00122,Choline
,31542713,EC50,"Compound 19, 2-(benzo[b]thiophen-3-yl)-3-hydroxy-6-methoxy-4H-chromen-4-one, exhibited a broad-spectrum activity against Leishmania spp. (EC50 1.9 μM for Leishmania infantum, 3.4 μM for L. donovani, 6.7 μM for L. major), Trypanosoma cruzi (EC50 7.5 μM) and T. brucei (EC50 0.8 μM).","Discovery of a benzothiophene-flavonol halting miltefosine and antimonial drug resistance in Leishmania parasites through the application of medicinal chemistry, screening and genomics. ",EC50-Q16,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31542713/),μM,7.5,13517,DB00122,Choline
,31542713,EC50,"Compound 19, 2-(benzo[b]thiophen-3-yl)-3-hydroxy-6-methoxy-4H-chromen-4-one, exhibited a broad-spectrum activity against Leishmania spp. (EC50 1.9 μM for Leishmania infantum, 3.4 μM for L. donovani, 6.7 μM for L. major), Trypanosoma cruzi (EC50 7.5 μM) and T. brucei (EC50 0.8 μM).","Discovery of a benzothiophene-flavonol halting miltefosine and antimonial drug resistance in Leishmania parasites through the application of medicinal chemistry, screening and genomics. ",EC50-Q16,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31542713/),μM,0.8,13518,DB00122,Choline
,31542713,half-life,In vivo pharmacokinetic studies indicated that compound 19 has a long half-life (intravenous (IV): 63.2 h; per os (PO): 46.9 h) with an acceptable ADME-Toxicity profile.,"Discovery of a benzothiophene-flavonol halting miltefosine and antimonial drug resistance in Leishmania parasites through the application of medicinal chemistry, screening and genomics. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31542713/),h,63.2,13519,DB00122,Choline
,31542713,half-life,In vivo pharmacokinetic studies indicated that compound 19 has a long half-life (intravenous (IV): 63.2 h; per os (PO): 46.9 h) with an acceptable ADME-Toxicity profile.,"Discovery of a benzothiophene-flavonol halting miltefosine and antimonial drug resistance in Leishmania parasites through the application of medicinal chemistry, screening and genomics. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31542713/),h,46.9,13520,DB00122,Choline
,3609075,clearance,"In 8 patients with normal function of the liver and the kidneys, the median clearance of N-PAB was 6.86 ml/min/kg and the median volume of distribution was 1.56 l/kg.",Pharmacokinetics of n-propyl-ajmaline-bitartrate in elderly patients with ventricular ectopic activity. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3609075/),[ml] / [kg·min],6.86,16372,DB00122,Choline
,3609075,volume of distribution,"In 8 patients with normal function of the liver and the kidneys, the median clearance of N-PAB was 6.86 ml/min/kg and the median volume of distribution was 1.56 l/kg.",Pharmacokinetics of n-propyl-ajmaline-bitartrate in elderly patients with ventricular ectopic activity. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3609075/),[l] / [kg],1.56,16373,DB00122,Choline
,3609075,clearance,Two patients had a clearly diminished clearance of 1.58 ml/min/kg without obvious impairment of liver or renal function.,Pharmacokinetics of n-propyl-ajmaline-bitartrate in elderly patients with ventricular ectopic activity. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3609075/),[ml] / [kg·min],1.58,16374,DB00122,Choline
,3609075,clearance,One patient with chronic glomerulonephritis (plasma creatinine 3.4 mg/dl) had a N-PAB clearance of 2.79 ml/min/kg.,Pharmacokinetics of n-propyl-ajmaline-bitartrate in elderly patients with ventricular ectopic activity. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3609075/),[ml] / [kg·min],2.79,16375,DB00122,Choline
,33435009,zeta potential,"The average size of the prepared blank (MCM-41B) and drug-loaded MSNs (MCM-41L) was 114 ± 2.0 and 145 ± 0.4 nm with the zeta potential of approximately -43.5 ± 1.1 and -37.6 ± 1.4 mV, respectively.",MCM-41 Nanoparticles for Brain Delivery: Better Choline-Esterase and Amyloid Formation Inhibition with Improved Kinetics. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/33435009/),mv,43.5,19842,DB00122,Choline
,33435009,zeta potential,"The average size of the prepared blank (MCM-41B) and drug-loaded MSNs (MCM-41L) was 114 ± 2.0 and 145 ± 0.4 nm with the zeta potential of approximately -43.5 ± 1.1 and -37.6 ± 1.4 mV, respectively.",MCM-41 Nanoparticles for Brain Delivery: Better Choline-Esterase and Amyloid Formation Inhibition with Improved Kinetics. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/33435009/),mv,-,19843,DB00122,Choline
,33435009,zeta potential,"The average size of the prepared blank (MCM-41B) and drug-loaded MSNs (MCM-41L) was 114 ± 2.0 and 145 ± 0.4 nm with the zeta potential of approximately -43.5 ± 1.1 and -37.6 ± 1.4 mV, respectively.",MCM-41 Nanoparticles for Brain Delivery: Better Choline-Esterase and Amyloid Formation Inhibition with Improved Kinetics. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/33435009/),mv,37.6,19844,DB00122,Choline
,33435009,entrapment efficiency,MCM-41L exhibited an average entrapment efficiency of 88%.,MCM-41 Nanoparticles for Brain Delivery: Better Choline-Esterase and Amyloid Formation Inhibition with Improved Kinetics. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/33435009/),%,88,19845,DB00122,Choline
,33435009,AUC,In vivo pharmacokinetics in Wistar rats revealed that the AUC and mean residence time (MRT) for MCM-41L was sustained and significantly higher (p < 0.05) (780 ± 3.30 ng/L; 5.49 ± 0.25 h) compared to RTG solution (430 ± 3.50 ng/L; 0.768 ± 0.17 h).,MCM-41 Nanoparticles for Brain Delivery: Better Choline-Esterase and Amyloid Formation Inhibition with Improved Kinetics. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/33435009/),[ng] / [l],780,19846,DB00122,Choline
,33435009,AUC,In vivo pharmacokinetics in Wistar rats revealed that the AUC and mean residence time (MRT) for MCM-41L was sustained and significantly higher (p < 0.05) (780 ± 3.30 ng/L; 5.49 ± 0.25 h) compared to RTG solution (430 ± 3.50 ng/L; 0.768 ± 0.17 h).,MCM-41 Nanoparticles for Brain Delivery: Better Choline-Esterase and Amyloid Formation Inhibition with Improved Kinetics. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/33435009/),[ng] / [l],430,19847,DB00122,Choline
,33435009,mean residence time (MRT),In vivo pharmacokinetics in Wistar rats revealed that the AUC and mean residence time (MRT) for MCM-41L was sustained and significantly higher (p < 0.05) (780 ± 3.30 ng/L; 5.49 ± 0.25 h) compared to RTG solution (430 ± 3.50 ng/L; 0.768 ± 0.17 h).,MCM-41 Nanoparticles for Brain Delivery: Better Choline-Esterase and Amyloid Formation Inhibition with Improved Kinetics. ,MRT-Q53,[Article Link](https://pubmed.ncbi.nlm.nih.gov/33435009/),h,5.49,19848,DB00122,Choline
,33435009,mean residence time (MRT),In vivo pharmacokinetics in Wistar rats revealed that the AUC and mean residence time (MRT) for MCM-41L was sustained and significantly higher (p < 0.05) (780 ± 3.30 ng/L; 5.49 ± 0.25 h) compared to RTG solution (430 ± 3.50 ng/L; 0.768 ± 0.17 h).,MCM-41 Nanoparticles for Brain Delivery: Better Choline-Esterase and Amyloid Formation Inhibition with Improved Kinetics. ,MRT-Q53,[Article Link](https://pubmed.ncbi.nlm.nih.gov/33435009/),h,0.768,19849,DB00122,Choline
,21619725,terminal half-lives,"Pharmacokinetic key parameters were subject to interindividual variation of potential forensic importance, with terminal half-lives of 1-3 h indicating a detection interval of 8-24 h for SMC in plasma.",Pharmacokinetic properties of succinylmonocholine in surgical patients. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/21619725/),h,1-3,20945,DB00122,Choline
,9266276,A2,Both the parent drug and the metabolite exhibited potent in vitro inhibition of PAF-induced beta-TG release (A2 values of 4 and 1 nM respectively).,"Ex vivo inhibition of beta-thromboglobulin release following administration to man of ABT-299, a novel prodrug of a potent platelet activating factor antagonist. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9266276/),nM,4,21260,DB00122,Choline
,9266276,A2,Both the parent drug and the metabolite exhibited potent in vitro inhibition of PAF-induced beta-TG release (A2 values of 4 and 1 nM respectively).,"Ex vivo inhibition of beta-thromboglobulin release following administration to man of ABT-299, a novel prodrug of a potent platelet activating factor antagonist. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9266276/),nM,1,21261,DB00122,Choline
,24512295,en,"Optimized RA-loaded SLNs using tween 80 (SLNPRT) have the mean size of (149.2 ± 3.2 nm), ZP (-38.27 mV) entrapment efficiency (61.9 ± 2.2%).","Development, characterization and nasal delivery of rosmarinic acid-loaded solid lipid nanoparticles for the effective management of Huntington's disease. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24512295/),%,61.9,22238,DB00122,Choline
,24512295,brain drug concentration,"In the organ distribution study, brain drug concentration was found to be 5.69 µg, in pharmacokinetic study Cmax, tmax, t1/2, AUC values were found to be 0.284 µg/ml, 1.5 h, 3.17 h, and 1.505 µg/ml/h, respectively.","Development, characterization and nasal delivery of rosmarinic acid-loaded solid lipid nanoparticles for the effective management of Huntington's disease. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24512295/),μg,5.69,22239,DB00122,Choline
,24512295,Cmax,"In the organ distribution study, brain drug concentration was found to be 5.69 µg, in pharmacokinetic study Cmax, tmax, t1/2, AUC values were found to be 0.284 µg/ml, 1.5 h, 3.17 h, and 1.505 µg/ml/h, respectively.","Development, characterization and nasal delivery of rosmarinic acid-loaded solid lipid nanoparticles for the effective management of Huntington's disease. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24512295/),[μg] / [ml],0.284,22240,DB00122,Choline
,24512295,tmax,"In the organ distribution study, brain drug concentration was found to be 5.69 µg, in pharmacokinetic study Cmax, tmax, t1/2, AUC values were found to be 0.284 µg/ml, 1.5 h, 3.17 h, and 1.505 µg/ml/h, respectively.","Development, characterization and nasal delivery of rosmarinic acid-loaded solid lipid nanoparticles for the effective management of Huntington's disease. ",tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24512295/),h,1.5,22241,DB00122,Choline
,24512295,tmax,"In the organ distribution study, brain drug concentration was found to be 5.69 µg, in pharmacokinetic study Cmax, tmax, t1/2, AUC values were found to be 0.284 µg/ml, 1.5 h, 3.17 h, and 1.505 µg/ml/h, respectively.","Development, characterization and nasal delivery of rosmarinic acid-loaded solid lipid nanoparticles for the effective management of Huntington's disease. ",tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24512295/),h,3.17,22242,DB00122,Choline
,24512295,t1/2,"In the organ distribution study, brain drug concentration was found to be 5.69 µg, in pharmacokinetic study Cmax, tmax, t1/2, AUC values were found to be 0.284 µg/ml, 1.5 h, 3.17 h, and 1.505 µg/ml/h, respectively.","Development, characterization and nasal delivery of rosmarinic acid-loaded solid lipid nanoparticles for the effective management of Huntington's disease. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24512295/),h,1.5,22243,DB00122,Choline
,24512295,t1/2,"In the organ distribution study, brain drug concentration was found to be 5.69 µg, in pharmacokinetic study Cmax, tmax, t1/2, AUC values were found to be 0.284 µg/ml, 1.5 h, 3.17 h, and 1.505 µg/ml/h, respectively.","Development, characterization and nasal delivery of rosmarinic acid-loaded solid lipid nanoparticles for the effective management of Huntington's disease. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24512295/),h,3.17,22244,DB00122,Choline
,24512295,AUC,"In the organ distribution study, brain drug concentration was found to be 5.69 µg, in pharmacokinetic study Cmax, tmax, t1/2, AUC values were found to be 0.284 µg/ml, 1.5 h, 3.17 h, and 1.505 µg/ml/h, respectively.","Development, characterization and nasal delivery of rosmarinic acid-loaded solid lipid nanoparticles for the effective management of Huntington's disease. ",AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24512295/),[μg] / [h·ml],1.505,22245,DB00122,Choline
>,28607017,cellular accumulation ratio,"Pharmacokinetic studies in Plasmodium vinckei-infected mice indicated that albitiazolium rapidly and specifically accumulates to a great extent (cellular accumulation ratio, >150) in infected erythrocytes.",High Accumulation and In Vivo Recycling of the New Antimalarial Albitiazolium Lead to Rapid Parasite Death. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/28607017/),,150,27963,DB00122,Choline
,6893618,peak concentrations,"Average peak concentrations of theophylline in plasma (range, 15 mumol/L) were not significantly different when Nuelin, Brondecon and Choledyl tablets were administered to healthy subjects.",Comparative bioavailability study of theophylline tablets marketed in Australasia. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6893618/),[μM] / [l],15,28353,DB00122,Choline
,10956621,half-life,(125)I-SP-D was cleared with a half-life of 7 h from SP-D(-/-) mice vs. 13 h in SP-D(+/+) mice.,Surfactant metabolism in SP-D gene-targeted mice. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10956621/),h,7,33518,DB00122,Choline
,10956621,half-life,(125)I-SP-D was cleared with a half-life of 7 h from SP-D(-/-) mice vs. 13 h in SP-D(+/+) mice.,Surfactant metabolism in SP-D gene-targeted mice. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10956621/),h,13,33519,DB00122,Choline
,8478906,log,"To discover dual inhibitors of 5-lipoxygenase (LO) and cyclooxygenase (CO) with improved pharmacokinetic properties, we have designed and synthesized series of 1,2,4-triazole, 1,3,4-oxadiazole, and 1,3,4-thiadiazole di-tert-butylphenol derivatives which exhibit a wide range of log P (2.3 to > 4) and pKa (5.5-12) values.","Design of 5-(3,5-di-tert-butyl-4-hydroxyphenyl)-1,3,4-thiadiazoles, -1,3,4-oxadiazoles, and -1,2,4-triazoles as orally-active, nonulcerogenic antiinflammatory agents. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8478906/),,2.3 to > 4,34768,DB00122,Choline
,8478906,pKa,"To discover dual inhibitors of 5-lipoxygenase (LO) and cyclooxygenase (CO) with improved pharmacokinetic properties, we have designed and synthesized series of 1,2,4-triazole, 1,3,4-oxadiazole, and 1,3,4-thiadiazole di-tert-butylphenol derivatives which exhibit a wide range of log P (2.3 to > 4) and pKa (5.5-12) values.","Design of 5-(3,5-di-tert-butyl-4-hydroxyphenyl)-1,3,4-thiadiazoles, -1,3,4-oxadiazoles, and -1,2,4-triazoles as orally-active, nonulcerogenic antiinflammatory agents. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8478906/),,5.5-12,34769,DB00122,Choline
,8478906,IC50,"From this work 5-[3,5-bis(1,1-dimethylethyl)-4-hydroxyphenyl]-1,3,4-thiadiazole-2(3H)- thione, choline salt (12a, CI-986) was found to be a potent inhibitor of 5-LO (IC50 = 2.8 microM) and CO (IC50 = 0.8 microM), orally active in rat models of inflammation and nonulcerogenic.","Design of 5-(3,5-di-tert-butyl-4-hydroxyphenyl)-1,3,4-thiadiazoles, -1,3,4-oxadiazoles, and -1,2,4-triazoles as orally-active, nonulcerogenic antiinflammatory agents. ",IC50-Q10,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8478906/),μM,2.8,34770,DB00122,Choline
,8478906,IC50,"From this work 5-[3,5-bis(1,1-dimethylethyl)-4-hydroxyphenyl]-1,3,4-thiadiazole-2(3H)- thione, choline salt (12a, CI-986) was found to be a potent inhibitor of 5-LO (IC50 = 2.8 microM) and CO (IC50 = 0.8 microM), orally active in rat models of inflammation and nonulcerogenic.","Design of 5-(3,5-di-tert-butyl-4-hydroxyphenyl)-1,3,4-thiadiazoles, -1,3,4-oxadiazoles, and -1,2,4-triazoles as orally-active, nonulcerogenic antiinflammatory agents. ",IC50-Q10,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8478906/),μM,0.8,34771,DB00122,Choline
,16730362,terminal elimination half-life,"In terms of pharmacokinetics, the terminal elimination half-life is long (84h and 159h in rats and dogs respectively).",Development of miltefosine as an oral treatment for leishmaniasis. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/16730362/),h,84,35069,DB00122,Choline
,16730362,terminal elimination half-life,"In terms of pharmacokinetics, the terminal elimination half-life is long (84h and 159h in rats and dogs respectively).",Development of miltefosine as an oral treatment for leishmaniasis. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/16730362/),h,159,35070,DB00122,Choline
,8667228,"K,","The K, for inhibiting PAF binding to rabbit platelet membranes is 3.9 and 0.3 nM for human platelets.","Properties of ABT-299, a prodrug of A-85783, a highly potent platelet activating factor receptor antagonist. ",Ki-Q11,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8667228/),nM,3.9,35229,DB00122,Choline
,8667228,"K,","The K, for inhibiting PAF binding to rabbit platelet membranes is 3.9 and 0.3 nM for human platelets.","Properties of ABT-299, a prodrug of A-85783, a highly potent platelet activating factor receptor antagonist. ",Ki-Q11,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8667228/),nM,0.3,35230,DB00122,Choline
,8667228,potency (ED50),"When administered i.v., the potency (ED50) of ABT-299 for inhibiting PAF responses was between 6 to 10 micrograms/kg in the rat and mouse and 100 micrograms/kg in the guinea pig.","Properties of ABT-299, a prodrug of A-85783, a highly potent platelet activating factor receptor antagonist. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8667228/),[μg] / [kg],6 to 10,35231,DB00122,Choline
,8667228,potency (ED50),"When administered i.v., the potency (ED50) of ABT-299 for inhibiting PAF responses was between 6 to 10 micrograms/kg in the rat and mouse and 100 micrograms/kg in the guinea pig.","Properties of ABT-299, a prodrug of A-85783, a highly potent platelet activating factor receptor antagonist. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8667228/),[μg] / [kg],100,35232,DB00122,Choline
,8667228,ED50,"In addition to being active parenterally, ABT-299 exhibited p.o. activity in the rat and mouse (ED50 = 100 micrograms/kg in both species).","Properties of ABT-299, a prodrug of A-85783, a highly potent platelet activating factor receptor antagonist. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8667228/),[μg] / [kg],100,35233,DB00122,Choline
,16914220,radiation dose (BED(10)),Mean radiation dose (BED(10)) was 59.8 Gy (range 50.7-87.5 Gy in 13-28 fractions).,Phase I and pharmacokinetic study of combined treatment with perifosine and radiation in patients with advanced solid tumours. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16914220/),gy,59.8,36065,DB00122,Choline
,31683880,fractional excretion,"TMAO clearances were not significantly different from mGFR, with a mean ± SD TMAO fractional excretion of 105% ± 32%.",Elevation of Trimethylamine-N-Oxide in Chronic Kidney Disease: Contribution of Decreased Glomerular Filtration Rate. ,fe-Q44,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31683880/),%,105,36284,DB00122,Choline
,2636827,absolute bioavailability,The absolute bioavailability of nasal tetraethylammonium administration was 79%.,Nasal absorption of tetraethylammonium in rats. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2636827/),%,79,43833,DB00122,Choline
,3723649,T 1/2,This declined with T 1/2 [corrected] of 10 hours over a period of 50 hours.,Strychnine poisoning: clinical and toxicological observations on a non-fatal case. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3723649/),h,10,44757,DB00122,Choline
,8071816,detection limit,The detection limit of the assay was 200 pg/mL when a 0.1-mL plasma sample was used.,Radioimmunoassay for the novel platelet activating factor receptor antagonist E5880. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8071816/),[pg] / [ml],200,45938,DB00122,Choline
,8071816,initial plasma half-life,"The initial plasma half-life, including the distribution phase, was 0.26 h, and the plasma half-life of elimination was 9.96 h.",Radioimmunoassay for the novel platelet activating factor receptor antagonist E5880. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8071816/),h,0.26,45939,DB00122,Choline
,8071816,plasma half-life of elimination,"The initial plasma half-life, including the distribution phase, was 0.26 h, and the plasma half-life of elimination was 9.96 h.",Radioimmunoassay for the novel platelet activating factor receptor antagonist E5880. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/8071816/),h,9.96,45940,DB00122,Choline
,25678491,Parent fractions,"Parent fractions were 0.12 ± 0.4 after 20 min, necessitating individual metabolite corrections.",Quantification of 18F-fluorocholine kinetics in patients with prostate cancer. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25678491/),,0.12,50472,DB00122,Choline
,23213741,Tmax,"After intravenous drips of 0.62, 2.07 and 10.35 mg/kg ginkgolide B, parameters of pharmacokinetics of ginkgolide B were as follows: Tmax were 0.444, 1, 1 h; Cmax were 0.764, 3.024, 11.013 mg/L; AUC(0-1) were 1.007, 3.644, 16.646 mg x h/Lo.",[Study on pharmacokinetics of ginkgolide B injection in Beagle dogs]. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23213741/),h,0.444,50510,DB00122,Choline
,23213741,Tmax,"After intravenous drips of 0.62, 2.07 and 10.35 mg/kg ginkgolide B, parameters of pharmacokinetics of ginkgolide B were as follows: Tmax were 0.444, 1, 1 h; Cmax were 0.764, 3.024, 11.013 mg/L; AUC(0-1) were 1.007, 3.644, 16.646 mg x h/Lo.",[Study on pharmacokinetics of ginkgolide B injection in Beagle dogs]. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23213741/),h,1,50511,DB00122,Choline
,23213741,Cmax,"After intravenous drips of 0.62, 2.07 and 10.35 mg/kg ginkgolide B, parameters of pharmacokinetics of ginkgolide B were as follows: Tmax were 0.444, 1, 1 h; Cmax were 0.764, 3.024, 11.013 mg/L; AUC(0-1) were 1.007, 3.644, 16.646 mg x h/Lo.",[Study on pharmacokinetics of ginkgolide B injection in Beagle dogs]. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23213741/),[mg] / [l],0.764,50512,DB00122,Choline
,23213741,Cmax,"After intravenous drips of 0.62, 2.07 and 10.35 mg/kg ginkgolide B, parameters of pharmacokinetics of ginkgolide B were as follows: Tmax were 0.444, 1, 1 h; Cmax were 0.764, 3.024, 11.013 mg/L; AUC(0-1) were 1.007, 3.644, 16.646 mg x h/Lo.",[Study on pharmacokinetics of ginkgolide B injection in Beagle dogs]. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23213741/),[mg] / [l],3.024,50513,DB00122,Choline
,23213741,Cmax,"After intravenous drips of 0.62, 2.07 and 10.35 mg/kg ginkgolide B, parameters of pharmacokinetics of ginkgolide B were as follows: Tmax were 0.444, 1, 1 h; Cmax were 0.764, 3.024, 11.013 mg/L; AUC(0-1) were 1.007, 3.644, 16.646 mg x h/Lo.",[Study on pharmacokinetics of ginkgolide B injection in Beagle dogs]. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23213741/),[mg] / [l],11.013,50514,DB00122,Choline
,23213741,AUC(0-1),"After intravenous drips of 0.62, 2.07 and 10.35 mg/kg ginkgolide B, parameters of pharmacokinetics of ginkgolide B were as follows: Tmax were 0.444, 1, 1 h; Cmax were 0.764, 3.024, 11.013 mg/L; AUC(0-1) were 1.007, 3.644, 16.646 mg x h/Lo.",[Study on pharmacokinetics of ginkgolide B injection in Beagle dogs]. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23213741/),[h·mg] / [lo],1.007,50515,DB00122,Choline
,23213741,AUC(0-1),"After intravenous drips of 0.62, 2.07 and 10.35 mg/kg ginkgolide B, parameters of pharmacokinetics of ginkgolide B were as follows: Tmax were 0.444, 1, 1 h; Cmax were 0.764, 3.024, 11.013 mg/L; AUC(0-1) were 1.007, 3.644, 16.646 mg x h/Lo.",[Study on pharmacokinetics of ginkgolide B injection in Beagle dogs]. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23213741/),[h·mg] / [lo],3.644,50516,DB00122,Choline
,23213741,AUC(0-1),"After intravenous drips of 0.62, 2.07 and 10.35 mg/kg ginkgolide B, parameters of pharmacokinetics of ginkgolide B were as follows: Tmax were 0.444, 1, 1 h; Cmax were 0.764, 3.024, 11.013 mg/L; AUC(0-1) were 1.007, 3.644, 16.646 mg x h/Lo.",[Study on pharmacokinetics of ginkgolide B injection in Beagle dogs]. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23213741/),[h·mg] / [lo],16.646,50517,DB00122,Choline
,26861689,Cmax,"The pharmacokinetic analysis of CAL compared with chlorogenic acid (CA), showed a higher value of Cmax(6.42 ± 1.49 min versus 3.97 ± 0.39 min) and a delayed Tmax(15 min versus 10 min), with 1.29-fold increase in relative oral bioavailability.",Enhanced oral bioavailability and in vivo antioxidant activity of chlorogenic acid via liposomal formulation. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26861689/),min,6.42,52256,DB00122,Choline
,26861689,Cmax,"The pharmacokinetic analysis of CAL compared with chlorogenic acid (CA), showed a higher value of Cmax(6.42 ± 1.49 min versus 3.97 ± 0.39 min) and a delayed Tmax(15 min versus 10 min), with 1.29-fold increase in relative oral bioavailability.",Enhanced oral bioavailability and in vivo antioxidant activity of chlorogenic acid via liposomal formulation. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26861689/),min,3.97,52257,DB00122,Choline
,26861689,Tmax,"The pharmacokinetic analysis of CAL compared with chlorogenic acid (CA), showed a higher value of Cmax(6.42 ± 1.49 min versus 3.97 ± 0.39 min) and a delayed Tmax(15 min versus 10 min), with 1.29-fold increase in relative oral bioavailability.",Enhanced oral bioavailability and in vivo antioxidant activity of chlorogenic acid via liposomal formulation. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26861689/),min,15,52258,DB00122,Choline
,26861689,Tmax,"The pharmacokinetic analysis of CAL compared with chlorogenic acid (CA), showed a higher value of Cmax(6.42 ± 1.49 min versus 3.97 ± 0.39 min) and a delayed Tmax(15 min versus 10 min), with 1.29-fold increase in relative oral bioavailability.",Enhanced oral bioavailability and in vivo antioxidant activity of chlorogenic acid via liposomal formulation. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26861689/),min,10,52259,DB00122,Choline
,29757380,intracellular-to-plasma concentration ratio,Intracellular PBMC distribution was described with an intracellular-to-plasma concentration ratio of 2.17 [relative standard error (RSE) 4.9%] and intracellular distribution rate constant of 1.23 day-1 (RSE 14%).,Simultaneous population pharmacokinetic modelling of plasma and intracellular PBMC miltefosine concentrations in New World cutaneous leishmaniasis and exploration of exposure-response relationships. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/29757380/),,2.17,52999,DB00122,Choline
,29757380,intracellular distribution rate constant,Intracellular PBMC distribution was described with an intracellular-to-plasma concentration ratio of 2.17 [relative standard error (RSE) 4.9%] and intracellular distribution rate constant of 1.23 day-1 (RSE 14%).,Simultaneous population pharmacokinetic modelling of plasma and intracellular PBMC miltefosine concentrations in New World cutaneous leishmaniasis and exploration of exposure-response relationships. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/29757380/),1/[d],1.23,53000,DB00122,Choline
>,29757380,area under the plasma concentration-time curve,A proposed PK target for the area under the plasma concentration-time curve (day 0-28) of >535 mg·day/L corresponded to >95% probability of cure.,Simultaneous population pharmacokinetic modelling of plasma and intracellular PBMC miltefosine concentrations in New World cutaneous leishmaniasis and exploration of exposure-response relationships. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/29757380/),[d·mg] / [l],535,53001,DB00122,Choline
,34224964,enrichment factor (EF),The enrichment factor (EF) of the reversed lipid micelle-based HF-LPME for rotigotine reached 126.,Reversed lipid micellar hollow-fiber liquid-phase microextraction of rotigotine in rat plasma. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/34224964/),,126,58450,DB00122,Choline
,11028225,Terminal half-life t1/2,"Terminal half-life t1/2 of the drug in blood with free drug solution was about 12 hr, whereas with liposomes, a twofold increase in t1/2 was observed.",Biodistribution of liposomes of terbutaline sulfate in guinea pigs. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11028225/),h,12,62354,DB00122,Choline
,16013987,clinical half-life,The clinical half-life of miltefosine is approximately 7 days.,Miltefosine to treat leishmaniasis. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16013987/),d,7,63514,DB00122,Choline
less,1949894,bioavailability,"3. The bioavailability of the drug was low (less than or equal to 10%) for all monkeys, probably due to rapid first pass metabolism.","Metabolism of the platelet-activating factor antagonist (+/-)-trans-2-(3'-methoxy-5'-methylsulphonyl-4'-propoxyphenyl)-5-(3"",4"" ,5""- trimethoxyphenyl)tetrahydrofuran (L-659,989) in rhesus monkeys. ",F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1949894/),%,10,68998,DB00122,Choline
,8205134,terminal half-lives,"After intravenous administration, the plasma concentration-time curves in all species fitted a two-compartment model and the terminal half-lives in guinea pigs, dogs and monkeys (both poor and extensive metabolizers) were 4.77, 1.71, 5.34 and 1.07 h, respectively.","Development of radioimmunoassay for the novel platelet activating factor receptor antagonist, E6123, and its application to pharmacokinetics in laboratory animals. ","t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/8205134/),h,4.77,69820,DB00122,Choline
,8205134,terminal half-lives,"After intravenous administration, the plasma concentration-time curves in all species fitted a two-compartment model and the terminal half-lives in guinea pigs, dogs and monkeys (both poor and extensive metabolizers) were 4.77, 1.71, 5.34 and 1.07 h, respectively.","Development of radioimmunoassay for the novel platelet activating factor receptor antagonist, E6123, and its application to pharmacokinetics in laboratory animals. ","t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/8205134/),h,1.71,69821,DB00122,Choline
,8205134,terminal half-lives,"After intravenous administration, the plasma concentration-time curves in all species fitted a two-compartment model and the terminal half-lives in guinea pigs, dogs and monkeys (both poor and extensive metabolizers) were 4.77, 1.71, 5.34 and 1.07 h, respectively.","Development of radioimmunoassay for the novel platelet activating factor receptor antagonist, E6123, and its application to pharmacokinetics in laboratory animals. ","t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/8205134/),h,5.34,69822,DB00122,Choline
,8205134,terminal half-lives,"After intravenous administration, the plasma concentration-time curves in all species fitted a two-compartment model and the terminal half-lives in guinea pigs, dogs and monkeys (both poor and extensive metabolizers) were 4.77, 1.71, 5.34 and 1.07 h, respectively.","Development of radioimmunoassay for the novel platelet activating factor receptor antagonist, E6123, and its application to pharmacokinetics in laboratory animals. ","t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/8205134/),h,1.07,69823,DB00122,Choline
,8205134,bioavailabilities,"The mean bioavailabilities of E6123 in guinea pigs, dogs and monkeys (poor and extensive metabolizers) were 106.9, 45.7, 59.1 and 22.8%, respectively.","Development of radioimmunoassay for the novel platelet activating factor receptor antagonist, E6123, and its application to pharmacokinetics in laboratory animals. ",F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8205134/),%,106.9,69824,DB00122,Choline
,8205134,bioavailabilities,"The mean bioavailabilities of E6123 in guinea pigs, dogs and monkeys (poor and extensive metabolizers) were 106.9, 45.7, 59.1 and 22.8%, respectively.","Development of radioimmunoassay for the novel platelet activating factor receptor antagonist, E6123, and its application to pharmacokinetics in laboratory animals. ",F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8205134/),%,45.7,69825,DB00122,Choline
,8205134,bioavailabilities,"The mean bioavailabilities of E6123 in guinea pigs, dogs and monkeys (poor and extensive metabolizers) were 106.9, 45.7, 59.1 and 22.8%, respectively.","Development of radioimmunoassay for the novel platelet activating factor receptor antagonist, E6123, and its application to pharmacokinetics in laboratory animals. ",F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8205134/),%,59.1,69826,DB00122,Choline
,8205134,bioavailabilities,"The mean bioavailabilities of E6123 in guinea pigs, dogs and monkeys (poor and extensive metabolizers) were 106.9, 45.7, 59.1 and 22.8%, respectively.","Development of radioimmunoassay for the novel platelet activating factor receptor antagonist, E6123, and its application to pharmacokinetics in laboratory animals. ",F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8205134/),%,22.8,69827,DB00122,Choline
,26356793,area under the plasma concentration-time curve (AUC0-t),"Pharmacokinetic study showed area under the plasma concentration-time curve (AUC0-t) and Cmax for 20% CD-PEG-DOX8 micelles and DOX solution were 1336.58 ± 179.43 mg/L·h, 96.35 ± 3.32 mg/L and 1.40 ± 0.19 mg/L·h, 1.15 ± 0.25 mg/L, respectively.",Choline Derivate-Modified Doxorubicin Loaded Micelle for Glioma Therapy. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26356793/),[mg] / [h·l],1336.58,70484,DB00122,Choline
,26356793,area under the plasma concentration-time curve (AUC0-t),"Pharmacokinetic study showed area under the plasma concentration-time curve (AUC0-t) and Cmax for 20% CD-PEG-DOX8 micelles and DOX solution were 1336.58 ± 179.43 mg/L·h, 96.35 ± 3.32 mg/L and 1.40 ± 0.19 mg/L·h, 1.15 ± 0.25 mg/L, respectively.",Choline Derivate-Modified Doxorubicin Loaded Micelle for Glioma Therapy. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26356793/),[mg] / [l],96.35,70485,DB00122,Choline
,26356793,Cmax,"Pharmacokinetic study showed area under the plasma concentration-time curve (AUC0-t) and Cmax for 20% CD-PEG-DOX8 micelles and DOX solution were 1336.58 ± 179.43 mg/L·h, 96.35 ± 3.32 mg/L and 1.40 ± 0.19 mg/L·h, 1.15 ± 0.25 mg/L, respectively.",Choline Derivate-Modified Doxorubicin Loaded Micelle for Glioma Therapy. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26356793/),[mg] / [l],96.35,70486,DB00122,Choline
,26356793,Cmax,"Pharmacokinetic study showed area under the plasma concentration-time curve (AUC0-t) and Cmax for 20% CD-PEG-DOX8 micelles and DOX solution were 1336.58 ± 179.43 mg/L·h, 96.35 ± 3.32 mg/L and 1.40 ± 0.19 mg/L·h, 1.15 ± 0.25 mg/L, respectively.",Choline Derivate-Modified Doxorubicin Loaded Micelle for Glioma Therapy. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26356793/),[mg] / [h·l],1.40,70487,DB00122,Choline
,26356793,Cmax,"Pharmacokinetic study showed area under the plasma concentration-time curve (AUC0-t) and Cmax for 20% CD-PEG-DOX8 micelles and DOX solution were 1336.58 ± 179.43 mg/L·h, 96.35 ± 3.32 mg/L and 1.40 ± 0.19 mg/L·h, 1.15 ± 0.25 mg/L, respectively.",Choline Derivate-Modified Doxorubicin Loaded Micelle for Glioma Therapy. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26356793/),[mg] / [l],1.15,70488,DB00122,Choline
,15652207,total body elimination rate constant,"After this the elimination of arsenic was a slow process with a total body elimination rate constant of 0.023 h(-1), corresponding to a half-life of 30 h.",In vivo distribution of arsenic after i.p. injection of arsonoliposomes in balb-c mice. ,k-Q47,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15652207/),1/[h],0.023,72330,DB00122,Choline
,15652207,half-life,"After this the elimination of arsenic was a slow process with a total body elimination rate constant of 0.023 h(-1), corresponding to a half-life of 30 h.",In vivo distribution of arsenic after i.p. injection of arsonoliposomes in balb-c mice. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15652207/),h,30,72331,DB00122,Choline
,3373163,beta half-life,Both kinetic analyses showed the beta half-life for SCh to be approximately 5 min for all doses.,Correlation of plasma concentration and effects of succinylcholine in dogs. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/3373163/),min,5,75345,DB00122,Choline
less,3373163,distribution half-life,SCh has a distribution half-life of less than 1 min.,Correlation of plasma concentration and effects of succinylcholine in dogs. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3373163/),min,1,75346,DB00122,Choline
,15720781,clearance,"The drug showed nonlinear pharmacokinetics, with the clearance decreasing from 46.0 to 27.1 L h(-1) over a dose range of 160-480 mg.",A pharmacokinetic/pharmacodynamic model for a platelet activating factor antagonist based on data arising from Phase I studies. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15720781/),[l] / [h],46.,76777,DB00122,Choline
,15720781,clearance,"The drug showed nonlinear pharmacokinetics, with the clearance decreasing from 46.0 to 27.1 L h(-1) over a dose range of 160-480 mg.",A pharmacokinetic/pharmacodynamic model for a platelet activating factor antagonist based on data arising from Phase I studies. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15720781/),[l] / [h],27,76778,DB00122,Choline
,15720781,C50,"There was an apparent dose dependency within the C50 (concentration producing 50% of the maximum effect) but at higher doses most of the data was above the estimated C50 and when the data was analysed simultaneously a value of 17.57 ng mL(-1) was obtained for C50, with considerable intersubject variability (103%).",A pharmacokinetic/pharmacodynamic model for a platelet activating factor antagonist based on data arising from Phase I studies. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15720781/),[ng] / [ml],17.57,76779,DB00122,Choline
,1646613,tmax,"Following oral administrations (capsules) apafant is absorbed rapidly (tmax 1 to 2 h), there is linear pharmacokinetics for the mean plasma concentrations of apafant measured by RIA as well as for the areas under the curve (AUCs).","Pharmacodynamics, pharmacokinetics and safety profile of the new platelet-activating factor antagonist apafant in man. ",tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1646613/),h,1 to 2,81886,DB00122,Choline
,1646613,volume of distribution,"Approximately 60% of apafant is bound to plasma protein, the mean volume of distribution is 28 l, about 44% of an oral dose is excreted in the urine, the mean renal clearance is 192 ml/min.","Pharmacodynamics, pharmacokinetics and safety profile of the new platelet-activating factor antagonist apafant in man. ",V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1646613/),l,28,81887,DB00122,Choline
,1646613,renal clearance,"Approximately 60% of apafant is bound to plasma protein, the mean volume of distribution is 28 l, about 44% of an oral dose is excreted in the urine, the mean renal clearance is 192 ml/min.","Pharmacodynamics, pharmacokinetics and safety profile of the new platelet-activating factor antagonist apafant in man. ",CLR-Q26,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1646613/),[ml] / [min],192,81888,DB00122,Choline
>,33651812,Protein binding,Protein binding was >99% for miltefosine and amphotericin B in plasma and tissue homogenates.,Pharmacokinetic / pharmacodynamic relationships of liposomal amphotericin B and miltefosine in experimental visceral leishmaniasis. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/33651812/),%,99,82718,DB00122,Choline
,3768245,peak plasma theophylline concentration,On day 1 the mean peak plasma theophylline concentration was 5.4 +/- 1.0 (+/- s.e. mean) micrograms ml-1 4 h after the morning dose and 11.2 +/- 1.6 micrograms ml-1 4 h after the evening dose which were significantly (P less than 0.01) different.,Acute and chronic pharmacokinetics of asymmetrical doses of slow release choline theophyllinate in asthma. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3768245/),[μg] / [ml],5.4,82972,DB00122,Choline
,3768245,peak plasma theophylline concentration,On day 1 the mean peak plasma theophylline concentration was 5.4 +/- 1.0 (+/- s.e. mean) micrograms ml-1 4 h after the morning dose and 11.2 +/- 1.6 micrograms ml-1 4 h after the evening dose which were significantly (P less than 0.01) different.,Acute and chronic pharmacokinetics of asymmetrical doses of slow release choline theophyllinate in asthma. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3768245/),[μg] / [ml],11.2,82973,DB00122,Choline
,3768245,peak plasma concentrations,"During day 4 mean peak plasma concentrations of theophylline after the morning and larger evening dose were 13.2 +/- 1.3 and 12.1 +/- 1.4 micrograms ml-1 respectively, which were not significantly different.",Acute and chronic pharmacokinetics of asymmetrical doses of slow release choline theophyllinate in asthma. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3768245/),[μg] / [ml],13.2,82974,DB00122,Choline
,3768245,peak plasma concentrations,"During day 4 mean peak plasma concentrations of theophylline after the morning and larger evening dose were 13.2 +/- 1.3 and 12.1 +/- 1.4 micrograms ml-1 respectively, which were not significantly different.",Acute and chronic pharmacokinetics of asymmetrical doses of slow release choline theophyllinate in asthma. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3768245/),[μg] / [ml],12.1,82975,DB00122,Choline
,3768245,time to peak,"However the post-dose time to peak was significantly delayed at night (6 h) compared to the morning (2 h, P less than 0.001).",Acute and chronic pharmacokinetics of asymmetrical doses of slow release choline theophyllinate in asthma. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3768245/),h,6,82976,DB00122,Choline
,3768245,time to peak,"However the post-dose time to peak was significantly delayed at night (6 h) compared to the morning (2 h, P less than 0.001).",Acute and chronic pharmacokinetics of asymmetrical doses of slow release choline theophyllinate in asthma. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3768245/),h,2,82977,DB00122,Choline
,18676223,MICs,The respective MICs were higher using CAMHB (128 and 64 mg/L) than using TH broth (4 and 8 mg/L).,In vitro and in vivo activity of miltefosine against penicillin-sensitive and -resistant Streptococcus pneumoniae strains. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18676223/),[mg] / [l],128,84089,DB00122,Choline
,18676223,MICs,The respective MICs were higher using CAMHB (128 and 64 mg/L) than using TH broth (4 and 8 mg/L).,In vitro and in vivo activity of miltefosine against penicillin-sensitive and -resistant Streptococcus pneumoniae strains. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18676223/),[mg] / [l],64,84090,DB00122,Choline
,18676223,MICs,The respective MICs were higher using CAMHB (128 and 64 mg/L) than using TH broth (4 and 8 mg/L).,In vitro and in vivo activity of miltefosine against penicillin-sensitive and -resistant Streptococcus pneumoniae strains. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18676223/),[mg] / [l],4,84091,DB00122,Choline
,18676223,MICs,The respective MICs were higher using CAMHB (128 and 64 mg/L) than using TH broth (4 and 8 mg/L).,In vitro and in vivo activity of miltefosine against penicillin-sensitive and -resistant Streptococcus pneumoniae strains. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18676223/),[mg] / [l],8,84092,DB00122,Choline
,28165076,t1/2,"Their blood circulation half-life in vivo (t1/2, ∼10 h) was 20-fold longer than that of CTAB-Au NRs (t1/2, <30 min).",Zwitterionic gold nanorods: low toxicity and high photothermal efficacy for cancer therapy. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/28165076/),h,∼10,85617,DB00122,Choline
<,28165076,t1/2,"Their blood circulation half-life in vivo (t1/2, ∼10 h) was 20-fold longer than that of CTAB-Au NRs (t1/2, <30 min).",Zwitterionic gold nanorods: low toxicity and high photothermal efficacy for cancer therapy. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/28165076/),min,30,85618,DB00122,Choline
,27660724,oral bioavailability (F%),"The drug suffers from extensive first pass effect, resulting in a reduction of oral bioavailability (F%) to 50% and a short elimination half-life of 4 h; parameters necessitating its frequent administration.","Improved bioavailability of timolol maleate via transdermal transfersomal gel: Statistical optimization, characterization, and pharmacokinetic assessment. ",F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27660724/),%,50,85871,DB00122,Choline
,27660724,elimination half-life,"The drug suffers from extensive first pass effect, resulting in a reduction of oral bioavailability (F%) to 50% and a short elimination half-life of 4 h; parameters necessitating its frequent administration.","Improved bioavailability of timolol maleate via transdermal transfersomal gel: Statistical optimization, characterization, and pharmacokinetic assessment. ","t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/27660724/),h,4,85872,DB00122,Choline
,27660724,%EE,"The optimized transfersomal gel was prepared with 4.65:1 PC:SAA molar ratio, 3:1 solvent volumetric ratio, and 13 mg drug amount with particle size of 2.722 μm, %EE of 39.96%, and a release rate of 134.49 μg/cm(2)/h.","Improved bioavailability of timolol maleate via transdermal transfersomal gel: Statistical optimization, characterization, and pharmacokinetic assessment. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27660724/),%,39.96,85873,DB00122,Choline
,27660724,release rate,"The optimized transfersomal gel was prepared with 4.65:1 PC:SAA molar ratio, 3:1 solvent volumetric ratio, and 13 mg drug amount with particle size of 2.722 μm, %EE of 39.96%, and a release rate of 134.49 μg/cm(2)/h.","Improved bioavailability of timolol maleate via transdermal transfersomal gel: Statistical optimization, characterization, and pharmacokinetic assessment. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27660724/),[μg] / [cm(2)·h],134.49,85874,DB00122,Choline
,27660724,permeation rate,The permeation rate of the optimized formulation through the rat skin was excellent (151.53 μg/cm(2)/h) and showed four times increase in relative bioavailability with prolonged plasma profile up to 72 h compared with oral aqueous solution.,"Improved bioavailability of timolol maleate via transdermal transfersomal gel: Statistical optimization, characterization, and pharmacokinetic assessment. ",Papp-Q6,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27660724/),[μg] / [cm(2)·h],151.53,85875,DB00122,Choline
,4059318,half-life,The kinetics fitted well with a two compartment open model and showed a long lasting elimination phase with a half-life ranging from 2.0 to 2.6 days for the two doses and the two administration routes.,Evidence for a different metabolic behaviour of cytidine diphosphate choline after oral and intravenous administration to rats. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/4059318/),d,2.0 to 2.6,88250,DB00122,Choline
,6470965,"""trough"" concentrations","Mean ""trough"" concentrations fell within the therapeutic range (5-30 mg/dL) with either regimen and were relatively constant, indicating that the steady state had been reached.",Choline magnesium trisalicylate: comparative pharmacokinetic study of once-daily and twice-daily dosages. ,Ctrough-Q37,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6470965/),[mg] / [dl],5-30,89209,DB00122,Choline
,1550908,Kpf,"The Kpf values ranged from 30 to 75 in the different brain regions and showed decreasing concentrations in the following order: pons + medulla oblongata, basal ganglia, amygdala, hypothalamus, thalamus, mesencephalon, bulbus olfactorius + septum, hippocampus, frontal cortex, occipital cortex, cerebellum.",Brain regional pharmacokinetics of biperiden in rats. ,Papp-Q6,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1550908/),,30 to 75,90030,DB00122,Choline
,1550908,ACh levels,ACh levels in the various brain regions ranged from 8 to 44 ng g-1 tissue.,Brain regional pharmacokinetics of biperiden in rats. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1550908/),[ng] / [g],8 to 44,90031,DB00122,Choline
>,32201308,apparent solubility,CAGE provided excellent apparent solubility of SRF tosylate (> 500 mg/mL).,Oral delivery of sorafenib through spontaneous formation of ionic liquid nanocomplexes. ,Papp-Q6,[Article Link](https://pubmed.ncbi.nlm.nih.gov/32201308/),[mg] / [ml],500,91871,DB00122,Choline
,34283999,Tm,Short heating (5 min) to 42 °C increased HePC release from DPPG2-TSL (Tm = 41 °C) by a factor of two in comparison to body temperature (37 °C).,Evaluation of release and pharmacokinetics of hexadecylphosphocholine (miltefosine) in phosphatidyldiglycerol-based thermosensitive liposomes. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/34283999/),°c,41,92400,DB00122,Choline
,8484010,plasma concentrations,"When 10 micrograms/kg of TxB2 was intravenously administered to dogs in which endogenous production of prostanoids was blocked by aspirin, the plasma concentrations of 11-dehydro TxB2 before and 2, 5, 15, 60 min after TxB2 administration were 6.2 +/- 1.4, 54.2 +/- 5.0, 65.2 +/- 14.3, 65.2 +/- 16.4 and 31.0 +/- 7.5 pg/ml, while the corresponding TxB2 levels were 20.1 +/- 3.1, 3143.3 +/- 379.5, 1432.6 +/- 120.5, 356.8 +/- 38.9, and 128.9 +/- 13.6 pg/ml, respectively.",11-Dehydro thromboxane B2: a reliable parameter of thromboxane A2 production in dogs. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8484010/),,6,92633,DB00122,Choline
,8484010,plasma concentrations,"When 10 micrograms/kg of TxB2 was intravenously administered to dogs in which endogenous production of prostanoids was blocked by aspirin, the plasma concentrations of 11-dehydro TxB2 before and 2, 5, 15, 60 min after TxB2 administration were 6.2 +/- 1.4, 54.2 +/- 5.0, 65.2 +/- 14.3, 65.2 +/- 16.4 and 31.0 +/- 7.5 pg/ml, while the corresponding TxB2 levels were 20.1 +/- 3.1, 3143.3 +/- 379.5, 1432.6 +/- 120.5, 356.8 +/- 38.9, and 128.9 +/- 13.6 pg/ml, respectively.",11-Dehydro thromboxane B2: a reliable parameter of thromboxane A2 production in dogs. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8484010/),,54,92634,DB00122,Choline
,8484010,plasma concentrations,"When 10 micrograms/kg of TxB2 was intravenously administered to dogs in which endogenous production of prostanoids was blocked by aspirin, the plasma concentrations of 11-dehydro TxB2 before and 2, 5, 15, 60 min after TxB2 administration were 6.2 +/- 1.4, 54.2 +/- 5.0, 65.2 +/- 14.3, 65.2 +/- 16.4 and 31.0 +/- 7.5 pg/ml, while the corresponding TxB2 levels were 20.1 +/- 3.1, 3143.3 +/- 379.5, 1432.6 +/- 120.5, 356.8 +/- 38.9, and 128.9 +/- 13.6 pg/ml, respectively.",11-Dehydro thromboxane B2: a reliable parameter of thromboxane A2 production in dogs. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8484010/),,65.2,92635,DB00122,Choline
,8484010,plasma concentrations,"When 10 micrograms/kg of TxB2 was intravenously administered to dogs in which endogenous production of prostanoids was blocked by aspirin, the plasma concentrations of 11-dehydro TxB2 before and 2, 5, 15, 60 min after TxB2 administration were 6.2 +/- 1.4, 54.2 +/- 5.0, 65.2 +/- 14.3, 65.2 +/- 16.4 and 31.0 +/- 7.5 pg/ml, while the corresponding TxB2 levels were 20.1 +/- 3.1, 3143.3 +/- 379.5, 1432.6 +/- 120.5, 356.8 +/- 38.9, and 128.9 +/- 13.6 pg/ml, respectively.",11-Dehydro thromboxane B2: a reliable parameter of thromboxane A2 production in dogs. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8484010/),,65.2,92636,DB00122,Choline
,8484010,plasma concentrations,"When 10 micrograms/kg of TxB2 was intravenously administered to dogs in which endogenous production of prostanoids was blocked by aspirin, the plasma concentrations of 11-dehydro TxB2 before and 2, 5, 15, 60 min after TxB2 administration were 6.2 +/- 1.4, 54.2 +/- 5.0, 65.2 +/- 14.3, 65.2 +/- 16.4 and 31.0 +/- 7.5 pg/ml, while the corresponding TxB2 levels were 20.1 +/- 3.1, 3143.3 +/- 379.5, 1432.6 +/- 120.5, 356.8 +/- 38.9, and 128.9 +/- 13.6 pg/ml, respectively.",11-Dehydro thromboxane B2: a reliable parameter of thromboxane A2 production in dogs. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8484010/),,31.0,92637,DB00122,Choline
,8484010,plasma concentrations,"When 10 micrograms/kg of TxB2 was intravenously administered to dogs in which endogenous production of prostanoids was blocked by aspirin, the plasma concentrations of 11-dehydro TxB2 before and 2, 5, 15, 60 min after TxB2 administration were 6.2 +/- 1.4, 54.2 +/- 5.0, 65.2 +/- 14.3, 65.2 +/- 16.4 and 31.0 +/- 7.5 pg/ml, while the corresponding TxB2 levels were 20.1 +/- 3.1, 3143.3 +/- 379.5, 1432.6 +/- 120.5, 356.8 +/- 38.9, and 128.9 +/- 13.6 pg/ml, respectively.",11-Dehydro thromboxane B2: a reliable parameter of thromboxane A2 production in dogs. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8484010/),,1432.6,92638,DB00122,Choline
,8484010,plasma concentrations,"When 10 micrograms/kg of TxB2 was intravenously administered to dogs in which endogenous production of prostanoids was blocked by aspirin, the plasma concentrations of 11-dehydro TxB2 before and 2, 5, 15, 60 min after TxB2 administration were 6.2 +/- 1.4, 54.2 +/- 5.0, 65.2 +/- 14.3, 65.2 +/- 16.4 and 31.0 +/- 7.5 pg/ml, while the corresponding TxB2 levels were 20.1 +/- 3.1, 3143.3 +/- 379.5, 1432.6 +/- 120.5, 356.8 +/- 38.9, and 128.9 +/- 13.6 pg/ml, respectively.",11-Dehydro thromboxane B2: a reliable parameter of thromboxane A2 production in dogs. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8484010/),,356.8,92639,DB00122,Choline
,8484010,plasma concentrations,"When 10 micrograms/kg of TxB2 was intravenously administered to dogs in which endogenous production of prostanoids was blocked by aspirin, the plasma concentrations of 11-dehydro TxB2 before and 2, 5, 15, 60 min after TxB2 administration were 6.2 +/- 1.4, 54.2 +/- 5.0, 65.2 +/- 14.3, 65.2 +/- 16.4 and 31.0 +/- 7.5 pg/ml, while the corresponding TxB2 levels were 20.1 +/- 3.1, 3143.3 +/- 379.5, 1432.6 +/- 120.5, 356.8 +/- 38.9, and 128.9 +/- 13.6 pg/ml, respectively.",11-Dehydro thromboxane B2: a reliable parameter of thromboxane A2 production in dogs. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8484010/),,128.9,92640,DB00122,Choline
,8212733,bioavailabilities,"The mean bioavailabilities of E6123 in rat, guinea-pig and dog were about 65, 95 and 81%, respectively, but the values for monkey were again highly variable (range 32-99%).",Pharmacokinetics of a new thienodiazepine platelet activating factor receptor antagonist (E6123) in laboratory animals. Is there a metabolic polymorphism in the rhesus monkey? ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8212733/),%,65,95309,DB00122,Choline
,8212733,bioavailabilities,"The mean bioavailabilities of E6123 in rat, guinea-pig and dog were about 65, 95 and 81%, respectively, but the values for monkey were again highly variable (range 32-99%).",Pharmacokinetics of a new thienodiazepine platelet activating factor receptor antagonist (E6123) in laboratory animals. Is there a metabolic polymorphism in the rhesus monkey? ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8212733/),%,95,95310,DB00122,Choline
,8212733,bioavailabilities,"The mean bioavailabilities of E6123 in rat, guinea-pig and dog were about 65, 95 and 81%, respectively, but the values for monkey were again highly variable (range 32-99%).",Pharmacokinetics of a new thienodiazepine platelet activating factor receptor antagonist (E6123) in laboratory animals. Is there a metabolic polymorphism in the rhesus monkey? ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8212733/),%,81,95311,DB00122,Choline
,8212733,bioavailabilities,"The mean bioavailabilities of E6123 in rat, guinea-pig and dog were about 65, 95 and 81%, respectively, but the values for monkey were again highly variable (range 32-99%).",Pharmacokinetics of a new thienodiazepine platelet activating factor receptor antagonist (E6123) in laboratory animals. Is there a metabolic polymorphism in the rhesus monkey? ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8212733/),%,32-99,95312,DB00122,Choline
<,28615288,Ktapp,"In this study, we determined the Jmax and apparent Michaelis constant (Ktapp) values for six structurally distinct OCT2 substrates and found a strong correlation between Jmax and Ktapp; high-affinity substrates [Ktapp values <50 µM, including 1-methyl-4-phenylpyridinium, or 1-methyl-4-phenylpyridinium (MPP), and cimetidine] displayed systematically lower Jmax values (<50 pmol cm-2 min-1) than did low-affinity substrates (Ktapp >200 µM, including choline and metformin).",Correlation between Apparent Substrate Affinity and OCT2 Transport Turnover. ,Km -Q1,[Article Link](https://pubmed.ncbi.nlm.nih.gov/28615288/),μM,50,97592,DB00122,Choline
<,28615288,Jmax,"In this study, we determined the Jmax and apparent Michaelis constant (Ktapp) values for six structurally distinct OCT2 substrates and found a strong correlation between Jmax and Ktapp; high-affinity substrates [Ktapp values <50 µM, including 1-methyl-4-phenylpyridinium, or 1-methyl-4-phenylpyridinium (MPP), and cimetidine] displayed systematically lower Jmax values (<50 pmol cm-2 min-1) than did low-affinity substrates (Ktapp >200 µM, including choline and metformin).",Correlation between Apparent Substrate Affinity and OCT2 Transport Turnover. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/28615288/),[pM] / [(cm)^2·min],50,97593,DB00122,Choline
>,28615288,Ktapp,"In this study, we determined the Jmax and apparent Michaelis constant (Ktapp) values for six structurally distinct OCT2 substrates and found a strong correlation between Jmax and Ktapp; high-affinity substrates [Ktapp values <50 µM, including 1-methyl-4-phenylpyridinium, or 1-methyl-4-phenylpyridinium (MPP), and cimetidine] displayed systematically lower Jmax values (<50 pmol cm-2 min-1) than did low-affinity substrates (Ktapp >200 µM, including choline and metformin).",Correlation between Apparent Substrate Affinity and OCT2 Transport Turnover. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/28615288/),μM,200,97594,DB00122,Choline
,8068869,bioavailability,"The bioavailability of the parent drug, calculated by dose-normalized AUC and deconvolution methods, was only 10-15% from the low dose, but increased to approximately 40% following the high dose.","Pharmacokinetics of SDZ 64-412, a novel antiasthmatic agent, following intravenous, oral, and inhalation dosing in the rat. ",F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8068869/),%,10-15,99086,DB00122,Choline
,8068869,bioavailability,"The bioavailability of the parent drug, calculated by dose-normalized AUC and deconvolution methods, was only 10-15% from the low dose, but increased to approximately 40% following the high dose.","Pharmacokinetics of SDZ 64-412, a novel antiasthmatic agent, following intravenous, oral, and inhalation dosing in the rat. ",F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8068869/),%,40,99087,DB00122,Choline
,8068869,bioavailability,"The inhalation dose yielded a bioavailability of approximately 40%, and AUC of the drug in lungs was approximately 25 times greater than in blood.","Pharmacokinetics of SDZ 64-412, a novel antiasthmatic agent, following intravenous, oral, and inhalation dosing in the rat. ",F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8068869/),%,40,99088,DB00122,Choline
,22876684,Tmax,"After intravenous of 0.75, 3.75 and 14.0 mg/kg ginkgolide B, parameters of pharmacokinetics of ginkgolide B were: Tmax were all (0.083 +/- 0) h, Cmax were (422.312 +/- 14.203), (1608.467 +/- 226.677), (1987.036 +/- 237.202) microg/L, AUC0-1 were (533.833 +/- 114.943), (1786.029 +/- 137.066), (1943.44 +/- 415.892) microg x h/L. Ginkgolide",[Study on the pharmacokinetics of ginkgolide B for injection in rats]. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22876684/),h,0.083,105932,DB00122,Choline
,22876684,Cmax,"After intravenous of 0.75, 3.75 and 14.0 mg/kg ginkgolide B, parameters of pharmacokinetics of ginkgolide B were: Tmax were all (0.083 +/- 0) h, Cmax were (422.312 +/- 14.203), (1608.467 +/- 226.677), (1987.036 +/- 237.202) microg/L, AUC0-1 were (533.833 +/- 114.943), (1786.029 +/- 137.066), (1943.44 +/- 415.892) microg x h/L. Ginkgolide",[Study on the pharmacokinetics of ginkgolide B for injection in rats]. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22876684/),[μg] / [l],422.312,105933,DB00122,Choline
,22876684,Cmax,"After intravenous of 0.75, 3.75 and 14.0 mg/kg ginkgolide B, parameters of pharmacokinetics of ginkgolide B were: Tmax were all (0.083 +/- 0) h, Cmax were (422.312 +/- 14.203), (1608.467 +/- 226.677), (1987.036 +/- 237.202) microg/L, AUC0-1 were (533.833 +/- 114.943), (1786.029 +/- 137.066), (1943.44 +/- 415.892) microg x h/L. Ginkgolide",[Study on the pharmacokinetics of ginkgolide B for injection in rats]. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22876684/),[μg] / [l],1608.467,105934,DB00122,Choline
,22876684,Cmax,"After intravenous of 0.75, 3.75 and 14.0 mg/kg ginkgolide B, parameters of pharmacokinetics of ginkgolide B were: Tmax were all (0.083 +/- 0) h, Cmax were (422.312 +/- 14.203), (1608.467 +/- 226.677), (1987.036 +/- 237.202) microg/L, AUC0-1 were (533.833 +/- 114.943), (1786.029 +/- 137.066), (1943.44 +/- 415.892) microg x h/L. Ginkgolide",[Study on the pharmacokinetics of ginkgolide B for injection in rats]. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22876684/),[μg] / [l],1987.036,105935,DB00122,Choline
,22876684,AUC0-1,"After intravenous of 0.75, 3.75 and 14.0 mg/kg ginkgolide B, parameters of pharmacokinetics of ginkgolide B were: Tmax were all (0.083 +/- 0) h, Cmax were (422.312 +/- 14.203), (1608.467 +/- 226.677), (1987.036 +/- 237.202) microg/L, AUC0-1 were (533.833 +/- 114.943), (1786.029 +/- 137.066), (1943.44 +/- 415.892) microg x h/L. Ginkgolide",[Study on the pharmacokinetics of ginkgolide B for injection in rats]. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22876684/),[h·μg] / [l],533.833,105936,DB00122,Choline
,22876684,AUC0-1,"After intravenous of 0.75, 3.75 and 14.0 mg/kg ginkgolide B, parameters of pharmacokinetics of ginkgolide B were: Tmax were all (0.083 +/- 0) h, Cmax were (422.312 +/- 14.203), (1608.467 +/- 226.677), (1987.036 +/- 237.202) microg/L, AUC0-1 were (533.833 +/- 114.943), (1786.029 +/- 137.066), (1943.44 +/- 415.892) microg x h/L. Ginkgolide",[Study on the pharmacokinetics of ginkgolide B for injection in rats]. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22876684/),[h·μg] / [l],1786.029,105937,DB00122,Choline
,22876684,AUC0-1,"After intravenous of 0.75, 3.75 and 14.0 mg/kg ginkgolide B, parameters of pharmacokinetics of ginkgolide B were: Tmax were all (0.083 +/- 0) h, Cmax were (422.312 +/- 14.203), (1608.467 +/- 226.677), (1987.036 +/- 237.202) microg/L, AUC0-1 were (533.833 +/- 114.943), (1786.029 +/- 137.066), (1943.44 +/- 415.892) microg x h/L. Ginkgolide",[Study on the pharmacokinetics of ginkgolide B for injection in rats]. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22876684/),[h·μg] / [l],1943.44,105938,DB00122,Choline
,7712674,time to maximal activity,"The mathematic analysis of the effects of ciprofloxacin showed that time to maximal activity was between 10.4 hours (PAF-dependent [Ca2+]i increase), and 15 hours (fMLP-induced superoxide anion and chemiluminescence production).",Pharmacokinetics and pharmacodynamics of neutrophil-associated ciprofloxacin in humans. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7712674/),h,10.4,108356,DB00122,Choline
,7712674,time to maximal activity,"The mathematic analysis of the effects of ciprofloxacin showed that time to maximal activity was between 10.4 hours (PAF-dependent [Ca2+]i increase), and 15 hours (fMLP-induced superoxide anion and chemiluminescence production).",Pharmacokinetics and pharmacodynamics of neutrophil-associated ciprofloxacin in humans. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7712674/),h,15,108357,DB00122,Choline
,7712674,time to maximal activity,"In addition, time to maximal activity and half-life differed in PMNs and in plasma (4.66 versus 1.90 hours and 13.03 versus 7.28 hours, respectively).",Pharmacokinetics and pharmacodynamics of neutrophil-associated ciprofloxacin in humans. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7712674/),h,4.66,108358,DB00122,Choline
,7712674,time to maximal activity,"In addition, time to maximal activity and half-life differed in PMNs and in plasma (4.66 versus 1.90 hours and 13.03 versus 7.28 hours, respectively).",Pharmacokinetics and pharmacodynamics of neutrophil-associated ciprofloxacin in humans. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7712674/),h,1.90,108359,DB00122,Choline
,7712674,half-life,"In addition, time to maximal activity and half-life differed in PMNs and in plasma (4.66 versus 1.90 hours and 13.03 versus 7.28 hours, respectively).",Pharmacokinetics and pharmacodynamics of neutrophil-associated ciprofloxacin in humans. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7712674/),h,1.90,108360,DB00122,Choline
,7712674,half-life,"In addition, time to maximal activity and half-life differed in PMNs and in plasma (4.66 versus 1.90 hours and 13.03 versus 7.28 hours, respectively).",Pharmacokinetics and pharmacodynamics of neutrophil-associated ciprofloxacin in humans. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7712674/),h,13.03,108361,DB00122,Choline
,7712674,half-life,"In addition, time to maximal activity and half-life differed in PMNs and in plasma (4.66 versus 1.90 hours and 13.03 versus 7.28 hours, respectively).",Pharmacokinetics and pharmacodynamics of neutrophil-associated ciprofloxacin in humans. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7712674/),h,7.28,108362,DB00122,Choline
,2031815,volume of distribution,Mean (SEM) volume of distribution was slightly greater with previous suxamethonium (143 (13) ml kg-1) than without (109 (5) ml kg-1) (P less than 0.04).,Pharmacokinetics and pharmacodynamics of atracurium with and without previous suxamethonium administration. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2031815/),[ml] / [kg],143,109862,DB00122,Choline
,2031815,volume of distribution,Mean (SEM) volume of distribution was slightly greater with previous suxamethonium (143 (13) ml kg-1) than without (109 (5) ml kg-1) (P less than 0.04).,Pharmacokinetics and pharmacodynamics of atracurium with and without previous suxamethonium administration. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2031815/),[ml] / [kg],109,109863,DB00122,Choline
,2031815,elimination half-life,"Mean elimination half-life was unaffected (20.3 (0.8) min and 20.4 (1.6) min, respectively).",Pharmacokinetics and pharmacodynamics of atracurium with and without previous suxamethonium administration. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/2031815/),min,20.3,109864,DB00122,Choline
,2031815,elimination half-life,"Mean elimination half-life was unaffected (20.3 (0.8) min and 20.4 (1.6) min, respectively).",Pharmacokinetics and pharmacodynamics of atracurium with and without previous suxamethonium administration. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/2031815/),min,20.4,109865,DB00122,Choline
,2031815,concentration at 50% block (Cpss50),Atracurium concentration at 50% block (Cpss50) was 305 (30) ng ml-1 with and 454 (25) ng ml-1 without previous suxamethonium (P less than 0.01).,Pharmacokinetics and pharmacodynamics of atracurium with and without previous suxamethonium administration. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2031815/),[ng] / [ml],305,109866,DB00122,Choline
,2031815,concentration at 50% block (Cpss50),Atracurium concentration at 50% block (Cpss50) was 305 (30) ng ml-1 with and 454 (25) ng ml-1 without previous suxamethonium (P less than 0.01).,Pharmacokinetics and pharmacodynamics of atracurium with and without previous suxamethonium administration. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2031815/),[ng] / [ml],454,109867,DB00122,Choline
,22432561,T(max),"Total CoQ(10) (T(max)) reached maximum plasma concentrations at 6.4 ± 2.5 hr after supplementation with CoQ(10) (NPN 02176955), 8.0 ± 9.8 hr with CoQ(10)-P5P-PC, and 9.5 ± 9.3 hr with CoQ(10) (DIN 02231736).","A randomized, double-blind, crossover study on the pharmacokinetics of a novel formulation of CoQ₁₀ with pyridoxal 5'-phosphate and phosphatidyl choline. ",tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22432561/),h,6.4,110285,DB00122,Choline
,22432561,T(max),"Total CoQ(10) (T(max)) reached maximum plasma concentrations at 6.4 ± 2.5 hr after supplementation with CoQ(10) (NPN 02176955), 8.0 ± 9.8 hr with CoQ(10)-P5P-PC, and 9.5 ± 9.3 hr with CoQ(10) (DIN 02231736).","A randomized, double-blind, crossover study on the pharmacokinetics of a novel formulation of CoQ₁₀ with pyridoxal 5'-phosphate and phosphatidyl choline. ",tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22432561/),h,8.0,110286,DB00122,Choline
,22432561,T(max),"Total CoQ(10) (T(max)) reached maximum plasma concentrations at 6.4 ± 2.5 hr after supplementation with CoQ(10) (NPN 02176955), 8.0 ± 9.8 hr with CoQ(10)-P5P-PC, and 9.5 ± 9.3 hr with CoQ(10) (DIN 02231736).","A randomized, double-blind, crossover study on the pharmacokinetics of a novel formulation of CoQ₁₀ with pyridoxal 5'-phosphate and phosphatidyl choline. ",tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22432561/),h,9.5,110287,DB00122,Choline
,22432561,elimination half-life (t(1/2)),"The estimated elimination half-life (t(1/2)) was 92.3 hr after a single oral dose of CoQ(10)-P5P-PC, 38.2 hr with CoQ(10) (NPN 02176955), and 80.7 hr with CoQ(10) (DIN 02231736).","A randomized, double-blind, crossover study on the pharmacokinetics of a novel formulation of CoQ₁₀ with pyridoxal 5'-phosphate and phosphatidyl choline. ","t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/22432561/),h,92.3,110288,DB00122,Choline
,22432561,elimination half-life (t(1/2)),"The estimated elimination half-life (t(1/2)) was 92.3 hr after a single oral dose of CoQ(10)-P5P-PC, 38.2 hr with CoQ(10) (NPN 02176955), and 80.7 hr with CoQ(10) (DIN 02231736).","A randomized, double-blind, crossover study on the pharmacokinetics of a novel formulation of CoQ₁₀ with pyridoxal 5'-phosphate and phosphatidyl choline. ","t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/22432561/),h,38.2,110289,DB00122,Choline
,22432561,elimination half-life (t(1/2)),"The estimated elimination half-life (t(1/2)) was 92.3 hr after a single oral dose of CoQ(10)-P5P-PC, 38.2 hr with CoQ(10) (NPN 02176955), and 80.7 hr with CoQ(10) (DIN 02231736).","A randomized, double-blind, crossover study on the pharmacokinetics of a novel formulation of CoQ₁₀ with pyridoxal 5'-phosphate and phosphatidyl choline. ","t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/22432561/),h,80.7,110290,DB00122,Choline
,10550569,C(max),"The pharmacokinetic parameters after a single intravenous dose of 40 mg/kg were calculated using a two-compartment model: C(max) = 1.6 +/- 0.3 micromol/ml, T(1/2alpha) = 0.18 +/- 0.09 h, T(1/2beta) = 3.3 +/- 0.88 h, clearance = 9.7 +/- 1.2 ml/h, AUC = 2.5 +/- 0.3 micromol/ml per h and Vss = 40.4 +/- 7.9 ml.","Erucylphosphocholine: pharmacokinetics, biodistribution and CNS-accumulation in the rat after intravenous administration. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10550569/),[μM] / [ml],1.6,112630,DB00122,Choline
,10550569,T(1/2alpha),"The pharmacokinetic parameters after a single intravenous dose of 40 mg/kg were calculated using a two-compartment model: C(max) = 1.6 +/- 0.3 micromol/ml, T(1/2alpha) = 0.18 +/- 0.09 h, T(1/2beta) = 3.3 +/- 0.88 h, clearance = 9.7 +/- 1.2 ml/h, AUC = 2.5 +/- 0.3 micromol/ml per h and Vss = 40.4 +/- 7.9 ml.","Erucylphosphocholine: pharmacokinetics, biodistribution and CNS-accumulation in the rat after intravenous administration. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10550569/),h,0.18,112631,DB00122,Choline
,10550569,T(1/2beta),"The pharmacokinetic parameters after a single intravenous dose of 40 mg/kg were calculated using a two-compartment model: C(max) = 1.6 +/- 0.3 micromol/ml, T(1/2alpha) = 0.18 +/- 0.09 h, T(1/2beta) = 3.3 +/- 0.88 h, clearance = 9.7 +/- 1.2 ml/h, AUC = 2.5 +/- 0.3 micromol/ml per h and Vss = 40.4 +/- 7.9 ml.","Erucylphosphocholine: pharmacokinetics, biodistribution and CNS-accumulation in the rat after intravenous administration. ","t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/10550569/),h,3.3,112632,DB00122,Choline
,10550569,clearance,"The pharmacokinetic parameters after a single intravenous dose of 40 mg/kg were calculated using a two-compartment model: C(max) = 1.6 +/- 0.3 micromol/ml, T(1/2alpha) = 0.18 +/- 0.09 h, T(1/2beta) = 3.3 +/- 0.88 h, clearance = 9.7 +/- 1.2 ml/h, AUC = 2.5 +/- 0.3 micromol/ml per h and Vss = 40.4 +/- 7.9 ml.","Erucylphosphocholine: pharmacokinetics, biodistribution and CNS-accumulation in the rat after intravenous administration. ",CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10550569/),[ml] / [h],9.7,112633,DB00122,Choline
,10550569,AUC,"The pharmacokinetic parameters after a single intravenous dose of 40 mg/kg were calculated using a two-compartment model: C(max) = 1.6 +/- 0.3 micromol/ml, T(1/2alpha) = 0.18 +/- 0.09 h, T(1/2beta) = 3.3 +/- 0.88 h, clearance = 9.7 +/- 1.2 ml/h, AUC = 2.5 +/- 0.3 micromol/ml per h and Vss = 40.4 +/- 7.9 ml.","Erucylphosphocholine: pharmacokinetics, biodistribution and CNS-accumulation in the rat after intravenous administration. ",AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10550569/),[μM] / [h·ml],2.5,112634,DB00122,Choline
,10550569,Vss,"The pharmacokinetic parameters after a single intravenous dose of 40 mg/kg were calculated using a two-compartment model: C(max) = 1.6 +/- 0.3 micromol/ml, T(1/2alpha) = 0.18 +/- 0.09 h, T(1/2beta) = 3.3 +/- 0.88 h, clearance = 9.7 +/- 1.2 ml/h, AUC = 2.5 +/- 0.3 micromol/ml per h and Vss = 40.4 +/- 7.9 ml.","Erucylphosphocholine: pharmacokinetics, biodistribution and CNS-accumulation in the rat after intravenous administration. ",Vss-Q65,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10550569/),ml,40.4,112635,DB00122,Choline
,10550569,brain to serum concentration ratios,The brain to serum concentration ratios averaged 2.1 after 2 weeks and 4.5 after 4 weeks.,"Erucylphosphocholine: pharmacokinetics, biodistribution and CNS-accumulation in the rat after intravenous administration. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10550569/),,2.1,112636,DB00122,Choline
,10550569,brain to serum concentration ratios,The brain to serum concentration ratios averaged 2.1 after 2 weeks and 4.5 after 4 weeks.,"Erucylphosphocholine: pharmacokinetics, biodistribution and CNS-accumulation in the rat after intravenous administration. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10550569/),,4.5,112637,DB00122,Choline
,32993976,binding rate,Folic acid was conjugated to bovine serum albumin by amide bond at a binding rate of 9.46 ± 0.49 folate molecules per bovine serum albumin.,"Resveratrol-loaded folate targeted lipoprotein-mimetic nanoparticles with improved cytotoxicity, antioxidant activity and pharmacokinetic profile. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/32993976/),molecules,9.46,114999,DB00122,Choline
,32993976,entrapment efficiency,"The particle size and entrapment efficiency of the developed nanoparticles was found to be 291.37 ± 3.81 nm and 91.96 ± 1.83%, respectively.","Resveratrol-loaded folate targeted lipoprotein-mimetic nanoparticles with improved cytotoxicity, antioxidant activity and pharmacokinetic profile. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/32993976/),%,91.96,115000,DB00122,Choline
>,32993976,circulation time,The pharmacokinetics studies after intravenous administration in healthy Wistar rats depicted that lipoprotein mimicking nanoparticles presented the longer circulation time (>48 h) compared to free drug which disappeared in few hours (6 h).,"Resveratrol-loaded folate targeted lipoprotein-mimetic nanoparticles with improved cytotoxicity, antioxidant activity and pharmacokinetic profile. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/32993976/),h,48,115001,DB00122,Choline
,32993976,circulation time,The pharmacokinetics studies after intravenous administration in healthy Wistar rats depicted that lipoprotein mimicking nanoparticles presented the longer circulation time (>48 h) compared to free drug which disappeared in few hours (6 h).,"Resveratrol-loaded folate targeted lipoprotein-mimetic nanoparticles with improved cytotoxicity, antioxidant activity and pharmacokinetic profile. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/32993976/),h,6,115002,DB00122,Choline
,1487948,half-life in the elimination phase,"Retention of both isotopes in plasma exceeded expectations, with a half-life in the elimination phase of 172.2 h for 3H and 69.7 h for 14C.",Prolonged retention of doubly labeled phosphatidylcholine in human plasma and erythrocytes after oral administration. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/1487948/),h,172.2,117681,DB00122,Choline
,1487948,half-life in the elimination phase,"Retention of both isotopes in plasma exceeded expectations, with a half-life in the elimination phase of 172.2 h for 3H and 69.7 h for 14C.",Prolonged retention of doubly labeled phosphatidylcholine in human plasma and erythrocytes after oral administration. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/1487948/),h,69.7,117682,DB00122,Choline
,18519729,first elimination half-life,"The pharmacokinetics of miltefosine could best be described by an open two-compartment disposition model, with a first elimination half-life of 7.05 days and a terminal elimination half-life of 30.9 days.",Pharmacokinetics of miltefosine in Old World cutaneous leishmaniasis patients. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/18519729/),d,7.05,119374,DB00122,Choline
,18519729,terminal elimination half-life,"The pharmacokinetics of miltefosine could best be described by an open two-compartment disposition model, with a first elimination half-life of 7.05 days and a terminal elimination half-life of 30.9 days.",Pharmacokinetics of miltefosine in Old World cutaneous leishmaniasis patients. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/18519729/),d,30.9,119375,DB00122,Choline
,27594083,absolute oral bioavailability,The absolute oral bioavailability was 93.4% for choline fenofibrate and 40.0% for fenofibric acid.,Absolute oral bioavailability of fenofibric acid and choline fenofibrate in rats determined by ultra-performance liquid chromatography tandem mass spectrometry. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27594083/),%,93.4,120311,DB00122,Choline
,27594083,absolute oral bioavailability,The absolute oral bioavailability was 93.4% for choline fenofibrate and 40.0% for fenofibric acid.,Absolute oral bioavailability of fenofibric acid and choline fenofibrate in rats determined by ultra-performance liquid chromatography tandem mass spectrometry. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27594083/),%,40.0,120312,DB00122,Choline
,3354232,half-lives,"2. After i.v. administration of 14C-MOTP, the plasma concentration of the drug declined biphasically with half-lives of 0.22 and 3.94 h in rats, and 0.81 and 8.00 h in dogs.",Metabolism and disposition of (RS)-2-methoxy-3-(octadecylcarbamoyloxy)propyl 2-(3-thiazolio)ethyl phosphate (MOTP) in rats and dogs. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3354232/),h,0.22,125853,DB00122,Choline
,3354232,half-lives,"2. After i.v. administration of 14C-MOTP, the plasma concentration of the drug declined biphasically with half-lives of 0.22 and 3.94 h in rats, and 0.81 and 8.00 h in dogs.",Metabolism and disposition of (RS)-2-methoxy-3-(octadecylcarbamoyloxy)propyl 2-(3-thiazolio)ethyl phosphate (MOTP) in rats and dogs. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3354232/),h,3.94,125854,DB00122,Choline
,3354232,half-lives,"2. After i.v. administration of 14C-MOTP, the plasma concentration of the drug declined biphasically with half-lives of 0.22 and 3.94 h in rats, and 0.81 and 8.00 h in dogs.",Metabolism and disposition of (RS)-2-methoxy-3-(octadecylcarbamoyloxy)propyl 2-(3-thiazolio)ethyl phosphate (MOTP) in rats and dogs. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3354232/),h,0.81,125855,DB00122,Choline
,3354232,half-lives,"2. After i.v. administration of 14C-MOTP, the plasma concentration of the drug declined biphasically with half-lives of 0.22 and 3.94 h in rats, and 0.81 and 8.00 h in dogs.",Metabolism and disposition of (RS)-2-methoxy-3-(octadecylcarbamoyloxy)propyl 2-(3-thiazolio)ethyl phosphate (MOTP) in rats and dogs. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3354232/),h,8.00,125856,DB00122,Choline
,19010871,maximum administered dose,The maximum administered dose was 330 mg/d where grade 3 fatigue was dose-limiting.,Phase I study of copper-binding agent ATN-224 in patients with advanced solid tumors. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19010871/),[mg] / [d],330,129075,DB00122,Choline
,19010871,time to achieve target ceruloplasmin,"At the maximum tolerated dose of 300 mg/d, the median time to achieve target ceruloplasmin was 21 days, and toxicities included grade 3 anemia, grade 3 neutropenia, fatigue, and sulfur eructation.",Phase I study of copper-binding agent ATN-224 in patients with advanced solid tumors. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19010871/),d,21,129076,DB00122,Choline
,6723760,maximum plasma concentrations,The maximum plasma concentrations were almost identical after administration in the morning and in the evening (12.6 +/- 3.3 mg X l-1 and 13.1 +/- 1.4 mg X l-1 respectively).,Chronopharmacokinetics of theophylline after sustained release and intravenous administration to adults. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6723760/),[mg] / [l],12.6,135521,DB00122,Choline
,6723760,maximum plasma concentrations,The maximum plasma concentrations were almost identical after administration in the morning and in the evening (12.6 +/- 3.3 mg X l-1 and 13.1 +/- 1.4 mg X l-1 respectively).,Chronopharmacokinetics of theophylline after sustained release and intravenous administration to adults. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6723760/),[mg] / [l],13.1,135522,DB00122,Choline
,6723760,c1 12,After administration of the tablets in the morning the plasma concentration 12 h post dosing was significantly lower than after administration in the evening: c1 12 accounted for 6.0 +/- 2.0 mg X l-1 after intake at 10 a.m. and for 7.9 +/- 2.1 mg X l-1 after ingestion at 10 p.m. (p less than 0.01).,Chronopharmacokinetics of theophylline after sustained release and intravenous administration to adults. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6723760/),[mg] / [l],6.0,135523,DB00122,Choline
,6723760,c1 12,After administration of the tablets in the morning the plasma concentration 12 h post dosing was significantly lower than after administration in the evening: c1 12 accounted for 6.0 +/- 2.0 mg X l-1 after intake at 10 a.m. and for 7.9 +/- 2.1 mg X l-1 after ingestion at 10 p.m. (p less than 0.01).,Chronopharmacokinetics of theophylline after sustained release and intravenous administration to adults. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6723760/),[mg] / [l],7.9,135524,DB00122,Choline
,6723760,c12,A similar observation was done after intravenous administration of the drug: c12 was 6.6 +/- 1.6 mg X l-1 after starting the infusion in the morning and 8.0 +/- 1.8 mg X l-1 after infusing the drug in the evening (p less than 0.01).,Chronopharmacokinetics of theophylline after sustained release and intravenous administration to adults. ,"K12, K21-Q48",[Article Link](https://pubmed.ncbi.nlm.nih.gov/6723760/),[mg] / [l],6.6,135525,DB00122,Choline
,6723760,c12,A similar observation was done after intravenous administration of the drug: c12 was 6.6 +/- 1.6 mg X l-1 after starting the infusion in the morning and 8.0 +/- 1.8 mg X l-1 after infusing the drug in the evening (p less than 0.01).,Chronopharmacokinetics of theophylline after sustained release and intravenous administration to adults. ,"K12, K21-Q48",[Article Link](https://pubmed.ncbi.nlm.nih.gov/6723760/),[mg] / [l],8.0,135526,DB00122,Choline
,27475453,flow rate,"MFS and Phenacetin (internal standard) were separated on Phenomenex Luna 3μ HILIC 200A (150×4.6mm) column under isocratic condition using methanol: 0.1% formic acid in triple distilled water, 90:10 (v/v) mobile phase at a flow rate of 0.8mL/min.",Pharmacokinetics and bioavailability assessment of Miltefosine in rats using high performance liquid chromatography tandem mass spectrometry. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27475453/),[ml] / [min],0.8,137734,DB00122,Choline
,27475453,total chromatographic run time,The total chromatographic run time was 4.0min.,Pharmacokinetics and bioavailability assessment of Miltefosine in rats using high performance liquid chromatography tandem mass spectrometry. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27475453/),min,4.0,137735,DB00122,Choline
,27475453,Cmax,"After oral administration, MFS showed Cmax (3200.00±95.39ng/mL) was observed at 12.00h (tmax) and t1/2 was 102.36±16.65h.",Pharmacokinetics and bioavailability assessment of Miltefosine in rats using high performance liquid chromatography tandem mass spectrometry. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27475453/),[ng] / [ml],3200.00,137736,DB00122,Choline
,27475453,tmax,"After oral administration, MFS showed Cmax (3200.00±95.39ng/mL) was observed at 12.00h (tmax) and t1/2 was 102.36±16.65h.",Pharmacokinetics and bioavailability assessment of Miltefosine in rats using high performance liquid chromatography tandem mass spectrometry. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27475453/),h,12.00,137737,DB00122,Choline
,27475453,t1/2,"After oral administration, MFS showed Cmax (3200.00±95.39ng/mL) was observed at 12.00h (tmax) and t1/2 was 102.36±16.65h.",Pharmacokinetics and bioavailability assessment of Miltefosine in rats using high performance liquid chromatography tandem mass spectrometry. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27475453/),h,102.36,137738,DB00122,Choline
,27475453,absolute bioavailability,The absolute bioavailability of MFS was 60.33±2.32%.,Pharmacokinetics and bioavailability assessment of Miltefosine in rats using high performance liquid chromatography tandem mass spectrometry. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27475453/),%,60.33,137739,DB00122,Choline
greater,26024820,Plasma concentrations,"Plasma concentrations greater than 1,000 ng/ml were maintained from 30 min to 8h, suggesting a sustained release pattern.",Novel fenofibric acid-loaded controlled release pellet bioequivalent to choline fenofibrate-loaded commercial product in beagle dogs. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26024820/),[ng] / [ml],"1,000",141110,DB00122,Choline
,25740692,Peak plasma concentrations (C max),"Peak plasma concentrations (C max) ranged from 11.7-19.3 µM, and remained >1 µM for >28 days.","Plasma and cerebrospinal fluid pharmacokinetics of the Akt inhibitor, perifosine, in a non-human primate model. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25740692/),μM,11.7-19.3,143123,DB00122,Choline
>,25740692,Peak plasma concentrations (C max),"Peak plasma concentrations (C max) ranged from 11.7-19.3 µM, and remained >1 µM for >28 days.","Plasma and cerebrospinal fluid pharmacokinetics of the Akt inhibitor, perifosine, in a non-human primate model. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25740692/),μM,1,143124,DB00122,Choline
,25740692,Time to C max (T max),Time to C max (T max) was 19 h.,"Plasma and cerebrospinal fluid pharmacokinetics of the Akt inhibitor, perifosine, in a non-human primate model. ",tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25740692/),h,19,143125,DB00122,Choline
,25740692,AUCPl,"The median (range) AUCPl was 3148 (2502-4705) µM/h, with a median (range) terminal half-life (t 1/2) of 193 (170-221) h.","Plasma and cerebrospinal fluid pharmacokinetics of the Akt inhibitor, perifosine, in a non-human primate model. ",AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25740692/),[μM] / [h],3148,143126,DB00122,Choline
,25740692,terminal half-life (t 1/2),"The median (range) AUCPl was 3148 (2502-4705) µM/h, with a median (range) terminal half-life (t 1/2) of 193 (170-221) h.","Plasma and cerebrospinal fluid pharmacokinetics of the Akt inhibitor, perifosine, in a non-human primate model. ","t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/25740692/),h,193,143127,DB00122,Choline
,25740692,Plasma clearance,Plasma clearance was 494 (329-637) mL/h/kg.,"Plasma and cerebrospinal fluid pharmacokinetics of the Akt inhibitor, perifosine, in a non-human primate model. ",CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25740692/),[ml] / [h·kg],494,143128,DB00122,Choline
,25740692,Peak CSF concentrations,Peak CSF concentrations were 4.1-10.1 nM (T max 64-235 h).,"Plasma and cerebrospinal fluid pharmacokinetics of the Akt inhibitor, perifosine, in a non-human primate model. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25740692/),nM,4.1-10.1,143129,DB00122,Choline
,25740692,T max,Peak CSF concentrations were 4.1-10.1 nM (T max 64-235 h).,"Plasma and cerebrospinal fluid pharmacokinetics of the Akt inhibitor, perifosine, in a non-human primate model. ",tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25740692/),h,64-235,143130,DB00122,Choline
,25740692,AUCs,"CSF AUCs and t 1/2 were 6358 (2266-7568) nM/h and 277 (146-350) h, respectively.","Plasma and cerebrospinal fluid pharmacokinetics of the Akt inhibitor, perifosine, in a non-human primate model. ",AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25740692/),[nM] / [h],6358,143131,DB00122,Choline
,25740692,t 1/2,"CSF AUCs and t 1/2 were 6358 (2266-7568) nM/h and 277 (146-350) h, respectively.","Plasma and cerebrospinal fluid pharmacokinetics of the Akt inhibitor, perifosine, in a non-human primate model. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25740692/),h,277,143132,DB00122,Choline
,25740692,CSF penetration,The mean CSF penetration was 0.16 %.,"Plasma and cerebrospinal fluid pharmacokinetics of the Akt inhibitor, perifosine, in a non-human primate model. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25740692/),%,0.16,143133,DB00122,Choline
,434904,Apparent volume of distribution,Apparent volume of distribution of theophylline in 12 infants was 0.71 +/- 0.18 1/kg (mean +/- SD).,"Dosage schedule for intravenous aminophylline in apnoea of prematurity, based on pharmacokinetic studies. ",V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/434904/),[1] / [kg],0.71,143893,DB00122,Choline
,434904,Plasma clearance rate,Plasma clearance rate measured in 11 infants at steady state was 18.6 +/- 4.8 ml/kg per hour.,"Dosage schedule for intravenous aminophylline in apnoea of prematurity, based on pharmacokinetic studies. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/434904/),[ml] / [h·kg],18.6,143894,DB00122,Choline
,26947181,log K,"The best-fit values for the 50% hemolysis data were log K=4.68, cm=110.8 mM, and cw=2.3 μM.",Hemolytic potential of miltefosine is dependent on cell concentration: Implications for in vitro cell cytotoxicity assays and pharmacokinetic data. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26947181/),,4.68,144114,DB00122,Choline
,26947181,cm,"The best-fit values for the 50% hemolysis data were log K=4.68, cm=110.8 mM, and cw=2.3 μM.",Hemolytic potential of miltefosine is dependent on cell concentration: Implications for in vitro cell cytotoxicity assays and pharmacokinetic data. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26947181/),mM,110.8,144115,DB00122,Choline
,26947181,cw,"The best-fit values for the 50% hemolysis data were log K=4.68, cm=110.8 mM, and cw=2.3 μM.",Hemolytic potential of miltefosine is dependent on cell concentration: Implications for in vitro cell cytotoxicity assays and pharmacokinetic data. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26947181/),μM,2.3,144116,DB00122,Choline
,18617603,Absolute plasma bioavailabilities,"Absolute plasma bioavailabilities (1, 3, and 5.6 mg/kg s.c.) were 80.3, 68.2, and 103.7%, respectively.","Pharmacokinetics of the novel nicotinic receptor antagonist N,N'-dodecane-1,12-diyl-bis-3-picolinium dibromide in the rat. ",F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18617603/),%,80.3,145004,DB00122,Choline
,18617603,Absolute plasma bioavailabilities,"Absolute plasma bioavailabilities (1, 3, and 5.6 mg/kg s.c.) were 80.3, 68.2, and 103.7%, respectively.","Pharmacokinetics of the novel nicotinic receptor antagonist N,N'-dodecane-1,12-diyl-bis-3-picolinium dibromide in the rat. ",F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18617603/),%,68.2,145005,DB00122,Choline
,18617603,Absolute plasma bioavailabilities,"Absolute plasma bioavailabilities (1, 3, and 5.6 mg/kg s.c.) were 80.3, 68.2, and 103.7%, respectively.","Pharmacokinetics of the novel nicotinic receptor antagonist N,N'-dodecane-1,12-diyl-bis-3-picolinium dibromide in the rat. ",F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18617603/),%,103.7,145006,DB00122,Choline
,18617603,Cmax,"bPiDDB (1, 3, and 5.6 mg/kg) gave Cmax values of 0.13, 0.33, and 0.43 microg/ml, respectively, Tmax values of 5.0, 6.7, and 8.8 min, respectively, and t1/2 values of 76.0, 54.6, and 41.7 min, respectively.","Pharmacokinetics of the novel nicotinic receptor antagonist N,N'-dodecane-1,12-diyl-bis-3-picolinium dibromide in the rat. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18617603/),[μg] / [ml],0.13,145007,DB00122,Choline
,18617603,Cmax,"bPiDDB (1, 3, and 5.6 mg/kg) gave Cmax values of 0.13, 0.33, and 0.43 microg/ml, respectively, Tmax values of 5.0, 6.7, and 8.8 min, respectively, and t1/2 values of 76.0, 54.6, and 41.7 min, respectively.","Pharmacokinetics of the novel nicotinic receptor antagonist N,N'-dodecane-1,12-diyl-bis-3-picolinium dibromide in the rat. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18617603/),[μg] / [ml],0.33,145008,DB00122,Choline
,18617603,Cmax,"bPiDDB (1, 3, and 5.6 mg/kg) gave Cmax values of 0.13, 0.33, and 0.43 microg/ml, respectively, Tmax values of 5.0, 6.7, and 8.8 min, respectively, and t1/2 values of 76.0, 54.6, and 41.7 min, respectively.","Pharmacokinetics of the novel nicotinic receptor antagonist N,N'-dodecane-1,12-diyl-bis-3-picolinium dibromide in the rat. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18617603/),[μg] / [ml],0.43,145009,DB00122,Choline
,18617603,Tmax,"bPiDDB (1, 3, and 5.6 mg/kg) gave Cmax values of 0.13, 0.33, and 0.43 microg/ml, respectively, Tmax values of 5.0, 6.7, and 8.8 min, respectively, and t1/2 values of 76.0, 54.6, and 41.7 min, respectively.","Pharmacokinetics of the novel nicotinic receptor antagonist N,N'-dodecane-1,12-diyl-bis-3-picolinium dibromide in the rat. ",tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18617603/),min,5.0,145010,DB00122,Choline
,18617603,Tmax,"bPiDDB (1, 3, and 5.6 mg/kg) gave Cmax values of 0.13, 0.33, and 0.43 microg/ml, respectively, Tmax values of 5.0, 6.7, and 8.8 min, respectively, and t1/2 values of 76.0, 54.6, and 41.7 min, respectively.","Pharmacokinetics of the novel nicotinic receptor antagonist N,N'-dodecane-1,12-diyl-bis-3-picolinium dibromide in the rat. ",tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18617603/),min,6.7,145011,DB00122,Choline
,18617603,Tmax,"bPiDDB (1, 3, and 5.6 mg/kg) gave Cmax values of 0.13, 0.33, and 0.43 microg/ml, respectively, Tmax values of 5.0, 6.7, and 8.8 min, respectively, and t1/2 values of 76.0, 54.6, and 41.7 min, respectively.","Pharmacokinetics of the novel nicotinic receptor antagonist N,N'-dodecane-1,12-diyl-bis-3-picolinium dibromide in the rat. ",tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18617603/),min,8.8,145012,DB00122,Choline
,18617603,t1/2,"bPiDDB (1, 3, and 5.6 mg/kg) gave Cmax values of 0.13, 0.33, and 0.43 microg/ml, respectively, Tmax values of 5.0, 6.7, and 8.8 min, respectively, and t1/2 values of 76.0, 54.6, and 41.7 min, respectively.","Pharmacokinetics of the novel nicotinic receptor antagonist N,N'-dodecane-1,12-diyl-bis-3-picolinium dibromide in the rat. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18617603/),min,76.0,145013,DB00122,Choline
,18617603,t1/2,"bPiDDB (1, 3, and 5.6 mg/kg) gave Cmax values of 0.13, 0.33, and 0.43 microg/ml, respectively, Tmax values of 5.0, 6.7, and 8.8 min, respectively, and t1/2 values of 76.0, 54.6, and 41.7 min, respectively.","Pharmacokinetics of the novel nicotinic receptor antagonist N,N'-dodecane-1,12-diyl-bis-3-picolinium dibromide in the rat. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18617603/),min,54.6,145014,DB00122,Choline
,18617603,t1/2,"bPiDDB (1, 3, and 5.6 mg/kg) gave Cmax values of 0.13, 0.33, and 0.43 microg/ml, respectively, Tmax values of 5.0, 6.7, and 8.8 min, respectively, and t1/2 values of 76.0, 54.6, and 41.7 min, respectively.","Pharmacokinetics of the novel nicotinic receptor antagonist N,N'-dodecane-1,12-diyl-bis-3-picolinium dibromide in the rat. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18617603/),min,41.7,145015,DB00122,Choline
,18617603,protein binding,"Only moderate protein binding (63-65% in plasma and 59-62% in brain supernatant) was observed, which was reversible.","Pharmacokinetics of the novel nicotinic receptor antagonist N,N'-dodecane-1,12-diyl-bis-3-picolinium dibromide in the rat. ",fu-Q46,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18617603/),%,63-65,145016,DB00122,Choline
,18617603,protein binding,"Only moderate protein binding (63-65% in plasma and 59-62% in brain supernatant) was observed, which was reversible.","Pharmacokinetics of the novel nicotinic receptor antagonist N,N'-dodecane-1,12-diyl-bis-3-picolinium dibromide in the rat. ",fu-Q46,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18617603/),%,59-62,145017,DB00122,Choline
,18617603,Brain/blood ratio,"Brain/blood ratio (0.18 at 5 min to 0.51 at 60 min after injection) was observed, indicating that clearance from brain is slower than clearance from plasma.","Pharmacokinetics of the novel nicotinic receptor antagonist N,N'-dodecane-1,12-diyl-bis-3-picolinium dibromide in the rat. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18617603/),,0.18,145018,DB00122,Choline
,18617603,Brain/blood ratio,"Brain/blood ratio (0.18 at 5 min to 0.51 at 60 min after injection) was observed, indicating that clearance from brain is slower than clearance from plasma.","Pharmacokinetics of the novel nicotinic receptor antagonist N,N'-dodecane-1,12-diyl-bis-3-picolinium dibromide in the rat. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18617603/),,0.51,145019,DB00122,Choline
,22954448,flow rate,"Chromatographic separation of oxaliplatin and the internal standard was achieved with a column modified with phosphorylcholine and an isocratic mobile phase (acetonitrile/water/acetic acid=90:10:0.1, v/v/v) at the flow rate of 0.2mL/min.",A full validated hydrophilic interaction liquid chromatography-tandem mass spectrometric method for the quantification of oxaliplatin in human plasma ultrafiltrates. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22954448/),[ml] / [min],0.2,145305,DB00122,Choline
,22954448,extraction recoveries,"The extraction recoveries from human plasma ultrafiltrates were 83.6-91.6%, and ion suppression caused by matrix components was 86.7-88.5% at three different levels, respectively.",A full validated hydrophilic interaction liquid chromatography-tandem mass spectrometric method for the quantification of oxaliplatin in human plasma ultrafiltrates. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22954448/),%,83.6-91.6,145306,DB00122,Choline
,22954448,ion suppression,"The extraction recoveries from human plasma ultrafiltrates were 83.6-91.6%, and ion suppression caused by matrix components was 86.7-88.5% at three different levels, respectively.",A full validated hydrophilic interaction liquid chromatography-tandem mass spectrometric method for the quantification of oxaliplatin in human plasma ultrafiltrates. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22954448/),%,86.7-88.5,145307,DB00122,Choline
,22954448,maximum concentration,The maximum concentration of colorectal cancer patient administered oxaliplatin was 1650ng/mL.,A full validated hydrophilic interaction liquid chromatography-tandem mass spectrometric method for the quantification of oxaliplatin in human plasma ultrafiltrates. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22954448/),[ng] / [ml],1650,145308,DB00122,Choline
,23739667,area under the concentration-time curve during the first 4 hours (AUC0-4),"The tumor GNP area under the concentration-time curve during the first 4 hours (AUC0-4) was 2.2 µg/ml h, representing 13% of the circulating blood GNP concentration over the same time period.",The biodistribution and pharmacokinetic evaluation of choline-bound gold nanoparticles in a human prostate tumor xenograft model. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23739667/),[μg] / [h·ml],2.2,146989,DB00122,Choline
,16170596,half-life,"Following i.v. administration in rats, it was very rapidly eliminated, mainly through renal excretion with a half-life of about 10 min.",Pharmacokinetic and pharmacodynamic evaluations of the zwitterionic metabolite of a new series of N-substituted soft anticholinergics. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16170596/),min,10,148791,DB00122,Choline
,12411790,degradation rate constant,"The mean degradation rate constant in plasma (1.07 +/- 0.49 min(-1)) was not different from the elimination rate constant (0.97 +/- 0.30 min(-1)), and an excellent correlation (r2 = 0.94) was observed.",Concentration-effect relation of succinylcholine chloride during propofol anesthesia. ,Kinact-Q14,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12411790/),1/[min],1.07,155392,DB00122,Choline
,12411790,elimination rate constant,"The mean degradation rate constant in plasma (1.07 +/- 0.49 min(-1)) was not different from the elimination rate constant (0.97 +/- 0.30 min(-1)), and an excellent correlation (r2 = 0.94) was observed.",Concentration-effect relation of succinylcholine chloride during propofol anesthesia. ,k-Q47,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12411790/),1/[min],0.97,155393,DB00122,Choline
,12411790,Total body clearance,Total body clearance derived using noncompartmental (37 +/- 7 ml x min(-1) x kg(-1)) and compartmental (37 +/- 9 ml x min(-1) x kg(-1)) approaches were similar.,Concentration-effect relation of succinylcholine chloride during propofol anesthesia. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12411790/),[ml] / [kg·min],37,155394,DB00122,Choline
,12411790,Total body clearance,Total body clearance derived using noncompartmental (37 +/- 7 ml x min(-1) x kg(-1)) and compartmental (37 +/- 9 ml x min(-1) x kg(-1)) approaches were similar.,Concentration-effect relation of succinylcholine chloride during propofol anesthesia. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12411790/),[ml] / [kg·min],37,155395,DB00122,Choline
,12411790,rate constant (k(eo)),"The plasma-effect compartment equilibration rate constant (k(eo)) was 0.058 +/- 0.026 min(-1), and the effect compartment concentration at 50% block was 734 +/- 211 ng/ml.",Concentration-effect relation of succinylcholine chloride during propofol anesthesia. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12411790/),1/[min],0.058,155396,DB00122,Choline
,12411790,effect compartment concentration at 50% block,"The plasma-effect compartment equilibration rate constant (k(eo)) was 0.058 +/- 0.026 min(-1), and the effect compartment concentration at 50% block was 734 +/- 211 ng/ml.",Concentration-effect relation of succinylcholine chloride during propofol anesthesia. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12411790/),[ng] / [ml],734,155397,DB00122,Choline
,8229782,ED50,"The arachidonic acid-induced mouse ear inflammation test allowed the evaluation of the antiedematous effects of BAY X1005 after topical (ED50, 18 micrograms/ear) and oral (ED50, 48.7 mg/kg) administration.","BAY X1005, a new inhibitor of leukotriene synthesis: in vivo inflammation pharmacology and pharmacokinetics. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8229782/),,18,155787,DB00122,Choline
,8229782,ED50,"The arachidonic acid-induced mouse ear inflammation test allowed the evaluation of the antiedematous effects of BAY X1005 after topical (ED50, 18 micrograms/ear) and oral (ED50, 48.7 mg/kg) administration.","BAY X1005, a new inhibitor of leukotriene synthesis: in vivo inflammation pharmacology and pharmacokinetics. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8229782/),mg,48.7,155788,DB00122,Choline
,8229782,ED50,"Profound inhibition of myeloperoxidase activity as a marker for phagocyte infiltration was seen (ED50, 3 micrograms/ear topically and 7.9 mg/kg p.o.) even 5 hr after application.","BAY X1005, a new inhibitor of leukotriene synthesis: in vivo inflammation pharmacology and pharmacokinetics. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8229782/),[μg] / [ear],3,155789,DB00122,Choline
,8229782,ED50,"Profound inhibition of myeloperoxidase activity as a marker for phagocyte infiltration was seen (ED50, 3 micrograms/ear topically and 7.9 mg/kg p.o.) even 5 hr after application.","BAY X1005, a new inhibitor of leukotriene synthesis: in vivo inflammation pharmacology and pharmacokinetics. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8229782/),mg,7,155790,DB00122,Choline
,8229782,ED50,"The rat whole blood ex vivo leukotriene B4 inhibition assay demonstrated that BAY X1005 was potent (ED50, 11.8 and 6.7 mg/kg p.o. at 1 and 5 hr, respectively) and had a long duration of action (16-hr ED40, 70 mg/kg p.o.).","BAY X1005, a new inhibitor of leukotriene synthesis: in vivo inflammation pharmacology and pharmacokinetics. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8229782/),[mg] / [kg],11.8,155791,DB00122,Choline
,8229782,ED50,"The rat whole blood ex vivo leukotriene B4 inhibition assay demonstrated that BAY X1005 was potent (ED50, 11.8 and 6.7 mg/kg p.o. at 1 and 5 hr, respectively) and had a long duration of action (16-hr ED40, 70 mg/kg p.o.).","BAY X1005, a new inhibitor of leukotriene synthesis: in vivo inflammation pharmacology and pharmacokinetics. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8229782/),[mg] / [kg],6.7,155792,DB00122,Choline
,8229782,ED50,"The rat whole blood ex vivo leukotriene B4 inhibition assay demonstrated that BAY X1005 was potent (ED50, 11.8 and 6.7 mg/kg p.o. at 1 and 5 hr, respectively) and had a long duration of action (16-hr ED40, 70 mg/kg p.o.).","BAY X1005, a new inhibitor of leukotriene synthesis: in vivo inflammation pharmacology and pharmacokinetics. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8229782/),,16,155793,DB00122,Choline
,8229782,ED50,"Similarly, inhibition of the zymosan-induced exudate leukotrienes B4 and C4 inhibition confirmed these data (ED50, 8.3 and 10.5 mg/kg p.o., respectively).","BAY X1005, a new inhibitor of leukotriene synthesis: in vivo inflammation pharmacology and pharmacokinetics. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8229782/),[mg] / [kg],8.3,155794,DB00122,Choline
,8229782,ED50,"Similarly, inhibition of the zymosan-induced exudate leukotrienes B4 and C4 inhibition confirmed these data (ED50, 8.3 and 10.5 mg/kg p.o., respectively).","BAY X1005, a new inhibitor of leukotriene synthesis: in vivo inflammation pharmacology and pharmacokinetics. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8229782/),[mg] / [kg],10.5,155795,DB00122,Choline
,8083562,peak concentration,Tropicamide was rapidly absorbed systemically with the mean peak concentration in plasma being 2.8 +/- 1.7 ng/ml (mean +/- SD) at five minutes after instillation.,Systemic absorption and anticholinergic activity of topically applied tropicamide. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8083562/),[ng] / [ml],2.8,160339,DB00122,Choline
,8083562,drug concentration,Tropicamide disappeared rapidly from the systemic circulation: drug concentration in plasma was 0.46 +/- 0.51 ng/ml (mean +/- SD) at 60 minutes and below 240 pg/ml at 120 minutes after instillation.,Systemic absorption and anticholinergic activity of topically applied tropicamide. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8083562/),[ng] / [ml],0.46,160340,DB00122,Choline
,8083562,apparent equilibrium binding constant (Ki-value,"Tropicamide bound to muscarinic receptors of rat brain with an apparent equilibrium binding constant (Ki-value in plasma) 220 +/- 25 nM (mean +/- SD, n = 3).",Systemic absorption and anticholinergic activity of topically applied tropicamide. ,Ki-Q11,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8083562/),nM,220,160341,DB00122,Choline
,29626123,SUVmean,"Results: SUVmean and K i P were 3.60 ± 2.16 and 0.28 ± 0.22 min-1 in lesions, compared with 2.11 ± 1.33 and 0.15 ± 0.10 min-1 in muscle and 0.26 ± 0.07 and 0.02 ± 0.01 min-1 in adipose tissue.",11C-Choline Pharmacokinetics in Recurrent Prostate Cancer. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/29626123/),1/[min],3.60,162095,DB00122,Choline
,29626123,SUVmean,"Results: SUVmean and K i P were 3.60 ± 2.16 and 0.28 ± 0.22 min-1 in lesions, compared with 2.11 ± 1.33 and 0.15 ± 0.10 min-1 in muscle and 0.26 ± 0.07 and 0.02 ± 0.01 min-1 in adipose tissue.",11C-Choline Pharmacokinetics in Recurrent Prostate Cancer. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/29626123/),1/[min],0.28,162096,DB00122,Choline
,29626123,SUVmean,"Results: SUVmean and K i P were 3.60 ± 2.16 and 0.28 ± 0.22 min-1 in lesions, compared with 2.11 ± 1.33 and 0.15 ± 0.10 min-1 in muscle and 0.26 ± 0.07 and 0.02 ± 0.01 min-1 in adipose tissue.",11C-Choline Pharmacokinetics in Recurrent Prostate Cancer. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/29626123/),1/[min],2.11,162097,DB00122,Choline
,29626123,K i P,"Results: SUVmean and K i P were 3.60 ± 2.16 and 0.28 ± 0.22 min-1 in lesions, compared with 2.11 ± 1.33 and 0.15 ± 0.10 min-1 in muscle and 0.26 ± 0.07 and 0.02 ± 0.01 min-1 in adipose tissue.",11C-Choline Pharmacokinetics in Recurrent Prostate Cancer. ,Ki-Q11,[Article Link](https://pubmed.ncbi.nlm.nih.gov/29626123/),1/[min],0.28,162098,DB00122,Choline
,29626123,K i P,"Results: SUVmean and K i P were 3.60 ± 2.16 and 0.28 ± 0.22 min-1 in lesions, compared with 2.11 ± 1.33 and 0.15 ± 0.10 min-1 in muscle and 0.26 ± 0.07 and 0.02 ± 0.01 min-1 in adipose tissue.",11C-Choline Pharmacokinetics in Recurrent Prostate Cancer. ,Ki-Q11,[Article Link](https://pubmed.ncbi.nlm.nih.gov/29626123/),1/[min],0.15,162099,DB00122,Choline
,29626123,K i P,"Results: SUVmean and K i P were 3.60 ± 2.16 and 0.28 ± 0.22 min-1 in lesions, compared with 2.11 ± 1.33 and 0.15 ± 0.10 min-1 in muscle and 0.26 ± 0.07 and 0.02 ± 0.01 min-1 in adipose tissue.",11C-Choline Pharmacokinetics in Recurrent Prostate Cancer. ,Ki-Q11,[Article Link](https://pubmed.ncbi.nlm.nih.gov/29626123/),1/[min],0.26,162100,DB00122,Choline
,29626123,K i P,"Results: SUVmean and K i P were 3.60 ± 2.16 and 0.28 ± 0.22 min-1 in lesions, compared with 2.11 ± 1.33 and 0.15 ± 0.10 min-1 in muscle and 0.26 ± 0.07 and 0.02 ± 0.01 min-1 in adipose tissue.",11C-Choline Pharmacokinetics in Recurrent Prostate Cancer. ,Ki-Q11,[Article Link](https://pubmed.ncbi.nlm.nih.gov/29626123/),1/[min],0.02,162101,DB00122,Choline
,29626123,K 1,"According to the Akaike information criterion, the 2-compartment irreversible model was most appropriate in 85% of lesions and resulted in a K 1 of 0.79 ± 0.98 min-1 (range, 0.11-7.17 min-1), a K 1/k 2 of 2.92 ± 3.52 (range, 0.31-20.00), a k 3 of 0.36 ± 0.30 min-1 (range, 0.00-1.00 min-1) and a K i C of 0.28 ± 0.22 min-1 (range, 0.00-1.33 min-1).",11C-Choline Pharmacokinetics in Recurrent Prostate Cancer. ,Ki-Q11,[Article Link](https://pubmed.ncbi.nlm.nih.gov/29626123/),1/[min],0.79,162102,DB00122,Choline
,29626123,K 1/k 2,"According to the Akaike information criterion, the 2-compartment irreversible model was most appropriate in 85% of lesions and resulted in a K 1 of 0.79 ± 0.98 min-1 (range, 0.11-7.17 min-1), a K 1/k 2 of 2.92 ± 3.52 (range, 0.31-20.00), a k 3 of 0.36 ± 0.30 min-1 (range, 0.00-1.00 min-1) and a K i C of 0.28 ± 0.22 min-1 (range, 0.00-1.33 min-1).",11C-Choline Pharmacokinetics in Recurrent Prostate Cancer. ,"λ1, λ2-Q67",[Article Link](https://pubmed.ncbi.nlm.nih.gov/29626123/),,2.92,162103,DB00122,Choline
,29626123,k 3,"According to the Akaike information criterion, the 2-compartment irreversible model was most appropriate in 85% of lesions and resulted in a K 1 of 0.79 ± 0.98 min-1 (range, 0.11-7.17 min-1), a K 1/k 2 of 2.92 ± 3.52 (range, 0.31-20.00), a k 3 of 0.36 ± 0.30 min-1 (range, 0.00-1.00 min-1) and a K i C of 0.28 ± 0.22 min-1 (range, 0.00-1.33 min-1).",11C-Choline Pharmacokinetics in Recurrent Prostate Cancer. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/29626123/),1/[min],0.36,162104,DB00122,Choline
,29626123,K i C,"According to the Akaike information criterion, the 2-compartment irreversible model was most appropriate in 85% of lesions and resulted in a K 1 of 0.79 ± 0.98 min-1 (range, 0.11-7.17 min-1), a K 1/k 2 of 2.92 ± 3.52 (range, 0.31-20.00), a k 3 of 0.36 ± 0.30 min-1 (range, 0.00-1.00 min-1) and a K i C of 0.28 ± 0.22 min-1 (range, 0.00-1.33 min-1).",11C-Choline Pharmacokinetics in Recurrent Prostate Cancer. ,Ki-Q11,[Article Link](https://pubmed.ncbi.nlm.nih.gov/29626123/),1/[min],0.28,162105,DB00122,Choline
,1768841,half-life,"According to this method, the half-life of hexadecylphosphocholine in serum rats is about 96 h.",Hexadecylphosphocholine: determination of serum concentrations in rats. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1768841/),h,96,164599,DB00122,Choline
,1768841,steady-state serum concentration,A steady-state serum concentration of 110 microM is reached after 2 weeks of daily treatment with 10 mg/kg hexadecylphosphocholine.,Hexadecylphosphocholine: determination of serum concentrations in rats. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1768841/),μM,110,164600,DB00122,Choline
,2037712,area under the curve,"The mean (+/- SD) area under the curve was 2668 (729) mg - hr/L and 2748 (716) mg - hr/L for CMT and CMT/sucralfate treatments, respectively.",Influence of sucralfate on trilisate bioavailability. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2037712/),[-·h·mg] / [l],2668,170066,DB00122,Choline
,2037712,area under the curve,"The mean (+/- SD) area under the curve was 2668 (729) mg - hr/L and 2748 (716) mg - hr/L for CMT and CMT/sucralfate treatments, respectively.",Influence of sucralfate on trilisate bioavailability. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2037712/),[-·h·mg] / [l],2748,170067,DB00122,Choline
,2037712,maximum concentration,"Mean (+/- SD) maximum concentration was 275 (69) mg/L and 283 (75) mg/L for CMT and CMT/sucralfate administrations, respectively.",Influence of sucralfate on trilisate bioavailability. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2037712/),[mg] / [l],275,170068,DB00122,Choline
,2037712,maximum concentration,"Mean (+/- SD) maximum concentration was 275 (69) mg/L and 283 (75) mg/L for CMT and CMT/sucralfate administrations, respectively.",Influence of sucralfate on trilisate bioavailability. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2037712/),[mg] / [l],283,170069,DB00122,Choline
,2037712,time to maximum concentration,"Mean (+/- SD) time to maximum concentration for CMT and CMT/sucralfate treatments was 1.8 (0.6) hours and 1.7 (0.7) hours, respectively.",Influence of sucralfate on trilisate bioavailability. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2037712/),h,1.8,170070,DB00122,Choline
,2037712,time to maximum concentration,"Mean (+/- SD) time to maximum concentration for CMT and CMT/sucralfate treatments was 1.8 (0.6) hours and 1.7 (0.7) hours, respectively.",Influence of sucralfate on trilisate bioavailability. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2037712/),h,1.7,170071,DB00122,Choline
,3263708,influx constant,"The influx constant for pyrrolidinocholine into intracranial tissue, Kin, was 0.017 ml/g/min (0.008 SD), and the initial volume of distribution, V0, was 0.08 ml/g (0.03 SD).",Influx of a choline analog to dog brain measured by positron emission tomography. ,Ki-Q11,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3263708/),[ml] / [g·min],0.017,170144,DB00122,Choline
,3263708,Kin,"The influx constant for pyrrolidinocholine into intracranial tissue, Kin, was 0.017 ml/g/min (0.008 SD), and the initial volume of distribution, V0, was 0.08 ml/g (0.03 SD).",Influx of a choline analog to dog brain measured by positron emission tomography. ,Ki-Q11,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3263708/),[ml] / [g·min],0.017,170145,DB00122,Choline
,3263708,"initial volume of distribution, V0","The influx constant for pyrrolidinocholine into intracranial tissue, Kin, was 0.017 ml/g/min (0.008 SD), and the initial volume of distribution, V0, was 0.08 ml/g (0.03 SD).",Influx of a choline analog to dog brain measured by positron emission tomography. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3263708/),[ml] / [g],0.08,170146,DB00122,Choline
,22881479,Half-life,Half-life values of DOX release ranged from 2 to 40 h at pH 5.0.,PolyMPC-doxorubicin prodrugs. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22881479/),h,2 to 40,171520,DB00122,Choline
,22881479,maximum tolerated dose,"Cell culture experiments showed that highly loaded polyMPC-DOX conjugates exhibited higher intracellular drug accumulation and lower half-maximal inhibitory concentration (IC(50)) values, while a polymer with 30 wt % drug loading showed a maximum tolerated dose in the range of 30-50 mg/kg DOX equivalent weight in healthy mice.",PolyMPC-doxorubicin prodrugs. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22881479/),[mg] / [kg],30-50,171521,DB00122,Choline
,9209610,half-life of elimination,"The mean half-life of elimination was 47 s with a 95% confidence interval of 24 to 70 s; that of effect compartment equilibration, 211 s with a 95% confidence range of 139 to 282 s.",Pharmacokinetics and pharmacodynamics of suxamethonium. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/9209610/),s,47,172779,DB00122,Choline
,9209610,half-life of elimination,"The mean half-life of elimination was 47 s with a 95% confidence interval of 24 to 70 s; that of effect compartment equilibration, 211 s with a 95% confidence range of 139 to 282 s.",Pharmacokinetics and pharmacodynamics of suxamethonium. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/9209610/),s,211,172780,DB00122,Choline
,1280178,EC50,Nebulized RP 58802B produced a rapid onset and long lasting inhibition of histamine-induced bronchospasm in the anaesthetized guinea-pig (EC50 = 3.2 +/- 0.9 micrograms/ml; duration greater than 90 min).,"RP 58802B, a long-acting beta 2-adrenoceptor agonist: assessment of antiasthma activity in the guinea-pig in vivo. ",EC50-Q16,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1280178/),[μg] / [ml],3.2,174504,DB00122,Choline
,1280178,time to severe dyspnoea,"In conscious guinea-pigs, RP 58802B (5 or 25 mg/kg, p.o. 60 min before challenge) significantly attenuated antigen-induced dyspnoea with the time to severe dyspnoea increasing from 170 +/- 32 to 325 +/- 32 s at the higher dose of drug.","RP 58802B, a long-acting beta 2-adrenoceptor agonist: assessment of antiasthma activity in the guinea-pig in vivo. ",tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1280178/),s,170,174505,DB00122,Choline
,1280178,time to severe dyspnoea,"In conscious guinea-pigs, RP 58802B (5 or 25 mg/kg, p.o. 60 min before challenge) significantly attenuated antigen-induced dyspnoea with the time to severe dyspnoea increasing from 170 +/- 32 to 325 +/- 32 s at the higher dose of drug.","RP 58802B, a long-acting beta 2-adrenoceptor agonist: assessment of antiasthma activity in the guinea-pig in vivo. ",tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1280178/),s,325,174506,DB00122,Choline
>,31236476,recovery,"Results: ACN precipitation and column elution effectively depleted matrix constituents-most notably choline-containing phospholipids-which are known to interfere with THC analysis, with average recovery values of >85% for plasma and >80% for brain.",Fast and Sensitive Quantification of Δ9-Tetrahydrocannabinol and Its Main Oxidative Metabolites by Liquid Chromatography/Tandem Mass Spectrometry. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31236476/),%,85,175087,DB00122,Choline
>,31236476,recovery,"Results: ACN precipitation and column elution effectively depleted matrix constituents-most notably choline-containing phospholipids-which are known to interfere with THC analysis, with average recovery values of >85% for plasma and >80% for brain.",Fast and Sensitive Quantification of Δ9-Tetrahydrocannabinol and Its Main Oxidative Metabolites by Liquid Chromatography/Tandem Mass Spectrometry. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31236476/),%,80,175088,DB00122,Choline
,31236476,total run time,The LC conditions yielded baseline separation of all analytes in a total run time of 7 min (including re-equilibration).,Fast and Sensitive Quantification of Δ9-Tetrahydrocannabinol and Its Main Oxidative Metabolites by Liquid Chromatography/Tandem Mass Spectrometry. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31236476/),min,7,175089,DB00122,Choline
,7891286,detection limit,"The detection limit was 2 pg/injection of PS, which was 20 times more sensitive than the conventional fluorescence detection.",Highly sensitive and specific determination of pravastatin sodium in plasma by high-performance liquid chromatography with laser-induced fluorescence detection after immobilized antibody extraction. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7891286/),[pg] / [injection],2,175592,DB00122,Choline
,7891286,maximum concentrations,"A single oral dose of PS in rats (20 mg/kg) and dogs (5 mg/kg) resulted in average maximum concentrations of 142 and 310 ng/mL, respectively.",Highly sensitive and specific determination of pravastatin sodium in plasma by high-performance liquid chromatography with laser-induced fluorescence detection after immobilized antibody extraction. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7891286/),[ng] / [ml],142,175593,DB00122,Choline
,7891286,maximum concentrations,"A single oral dose of PS in rats (20 mg/kg) and dogs (5 mg/kg) resulted in average maximum concentrations of 142 and 310 ng/mL, respectively.",Highly sensitive and specific determination of pravastatin sodium in plasma by high-performance liquid chromatography with laser-induced fluorescence detection after immobilized antibody extraction. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7891286/),[ng] / [ml],310,175594,DB00122,Choline
,31040642,area under the plasma concentration-time curve from time 0 to infinity,"Bioequivalence study showed that the mean area under the plasma concentration-time curve from time 0 to infinity of test tablet and reference soft capsule was 3.428±2.170 and 3.305±1.803 µg⋅h/mL, respectively; the mean Cmax was 0.365±0.158 and 0.380±0.108 µg/mL, respectively; and the mean Tmax was 3.51±2.57 and 3.85±3.19 hours, respectively.",Formulation and bioequivalence studies of choline alfoscerate tablet comparing with soft gelatin capsule in healthy male volunteers. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31040642/),[h·μg] / [ml],3.428,177534,DB00122,Choline
,31040642,area under the plasma concentration-time curve from time 0 to infinity,"Bioequivalence study showed that the mean area under the plasma concentration-time curve from time 0 to infinity of test tablet and reference soft capsule was 3.428±2.170 and 3.305±1.803 µg⋅h/mL, respectively; the mean Cmax was 0.365±0.158 and 0.380±0.108 µg/mL, respectively; and the mean Tmax was 3.51±2.57 and 3.85±3.19 hours, respectively.",Formulation and bioequivalence studies of choline alfoscerate tablet comparing with soft gelatin capsule in healthy male volunteers. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31040642/),[h·μg] / [ml],3.305,177535,DB00122,Choline
,31040642,Cmax,"Bioequivalence study showed that the mean area under the plasma concentration-time curve from time 0 to infinity of test tablet and reference soft capsule was 3.428±2.170 and 3.305±1.803 µg⋅h/mL, respectively; the mean Cmax was 0.365±0.158 and 0.380±0.108 µg/mL, respectively; and the mean Tmax was 3.51±2.57 and 3.85±3.19 hours, respectively.",Formulation and bioequivalence studies of choline alfoscerate tablet comparing with soft gelatin capsule in healthy male volunteers. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31040642/),[μg] / [ml],0.365,177536,DB00122,Choline
,31040642,Cmax,"Bioequivalence study showed that the mean area under the plasma concentration-time curve from time 0 to infinity of test tablet and reference soft capsule was 3.428±2.170 and 3.305±1.803 µg⋅h/mL, respectively; the mean Cmax was 0.365±0.158 and 0.380±0.108 µg/mL, respectively; and the mean Tmax was 3.51±2.57 and 3.85±3.19 hours, respectively.",Formulation and bioequivalence studies of choline alfoscerate tablet comparing with soft gelatin capsule in healthy male volunteers. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31040642/),[μg] / [ml],0.380,177537,DB00122,Choline
,31040642,Tmax,"Bioequivalence study showed that the mean area under the plasma concentration-time curve from time 0 to infinity of test tablet and reference soft capsule was 3.428±2.170 and 3.305±1.803 µg⋅h/mL, respectively; the mean Cmax was 0.365±0.158 and 0.380±0.108 µg/mL, respectively; and the mean Tmax was 3.51±2.57 and 3.85±3.19 hours, respectively.",Formulation and bioequivalence studies of choline alfoscerate tablet comparing with soft gelatin capsule in healthy male volunteers. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31040642/),h,3.51,177538,DB00122,Choline
,31040642,Tmax,"Bioequivalence study showed that the mean area under the plasma concentration-time curve from time 0 to infinity of test tablet and reference soft capsule was 3.428±2.170 and 3.305±1.803 µg⋅h/mL, respectively; the mean Cmax was 0.365±0.158 and 0.380±0.108 µg/mL, respectively; and the mean Tmax was 3.51±2.57 and 3.85±3.19 hours, respectively.",Formulation and bioequivalence studies of choline alfoscerate tablet comparing with soft gelatin capsule in healthy male volunteers. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31040642/),h,3.85,177539,DB00122,Choline
,3987803,tmax,"Food appeared to decrease the absorption rate of theophylline significantly, tmax being prolonged from 1.34 h (mean) to 4.40 h and cmax decreased from 7.82 mg . l-1 to 5.47 mg . l-1.",Food reduces the rate but not the extent of the absorption of theophylline from an aqueous solution. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3987803/),h,1.34,178385,DB00122,Choline
,3987803,tmax,"Food appeared to decrease the absorption rate of theophylline significantly, tmax being prolonged from 1.34 h (mean) to 4.40 h and cmax decreased from 7.82 mg . l-1 to 5.47 mg . l-1.",Food reduces the rate but not the extent of the absorption of theophylline from an aqueous solution. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3987803/),h,4.40,178386,DB00122,Choline
,3987803,cmax,"Food appeared to decrease the absorption rate of theophylline significantly, tmax being prolonged from 1.34 h (mean) to 4.40 h and cmax decreased from 7.82 mg . l-1 to 5.47 mg . l-1.",Food reduces the rate but not the extent of the absorption of theophylline from an aqueous solution. ,Emax-Q15,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3987803/),[mg] / [l],7.82,178387,DB00122,Choline
,3987803,cmax,"Food appeared to decrease the absorption rate of theophylline significantly, tmax being prolonged from 1.34 h (mean) to 4.40 h and cmax decreased from 7.82 mg . l-1 to 5.47 mg . l-1.",Food reduces the rate but not the extent of the absorption of theophylline from an aqueous solution. ,Emax-Q15,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3987803/),[mg] / [l],5.47,178388,DB00122,Choline
,17352269,total body clearance,"The total body clearance for cisplatin was 1.25 L/(hxm2) for the liposomal formulation, compared to 0.62 L/(hxm2) for conventional cisplatin.",Pharmacokinetics of liposomal cisplatin (lipoplatin) in combination with 5-FU in patients with advanced head and neck cancer: first results of a phase III study. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17352269/),[l] / [h·m2],1.25,184137,DB00122,Choline
,17352269,total body clearance,"The total body clearance for cisplatin was 1.25 L/(hxm2) for the liposomal formulation, compared to 0.62 L/(hxm2) for conventional cisplatin.",Pharmacokinetics of liposomal cisplatin (lipoplatin) in combination with 5-FU in patients with advanced head and neck cancer: first results of a phase III study. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17352269/),[l] / [h·m2],0.62,184138,DB00122,Choline
,17352269,terminal half life,The terminal half life was half as long for lipoplatin (10.98 h) as compared to cisplatin (24.5h).,Pharmacokinetics of liposomal cisplatin (lipoplatin) in combination with 5-FU in patients with advanced head and neck cancer: first results of a phase III study. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/17352269/),h,10.98,184139,DB00122,Choline
,17352269,terminal half life,The terminal half life was half as long for lipoplatin (10.98 h) as compared to cisplatin (24.5h).,Pharmacokinetics of liposomal cisplatin (lipoplatin) in combination with 5-FU in patients with advanced head and neck cancer: first results of a phase III study. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/17352269/),h,24.5,184140,DB00122,Choline
,17352269,area under the concentration time-curve (AUC),"Even though the maximum observed concentration in the plasma (C(max) was greater for lipoplatin than for cisplatin, the area under the concentration time-curve (AUC) was less (6.5 microg/ml vs. 4.07 microg/ml and 66.85 microg/h/ml vs. 130.33 microg/h/ml, respectively).",Pharmacokinetics of liposomal cisplatin (lipoplatin) in combination with 5-FU in patients with advanced head and neck cancer: first results of a phase III study. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17352269/),[μg] / [ml],6.5,184141,DB00122,Choline
,17352269,area under the concentration time-curve (AUC),"Even though the maximum observed concentration in the plasma (C(max) was greater for lipoplatin than for cisplatin, the area under the concentration time-curve (AUC) was less (6.5 microg/ml vs. 4.07 microg/ml and 66.85 microg/h/ml vs. 130.33 microg/h/ml, respectively).",Pharmacokinetics of liposomal cisplatin (lipoplatin) in combination with 5-FU in patients with advanced head and neck cancer: first results of a phase III study. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17352269/),[μg] / [ml],4.07,184142,DB00122,Choline
,17352269,area under the concentration time-curve (AUC),"Even though the maximum observed concentration in the plasma (C(max) was greater for lipoplatin than for cisplatin, the area under the concentration time-curve (AUC) was less (6.5 microg/ml vs. 4.07 microg/ml and 66.85 microg/h/ml vs. 130.33 microg/h/ml, respectively).",Pharmacokinetics of liposomal cisplatin (lipoplatin) in combination with 5-FU in patients with advanced head and neck cancer: first results of a phase III study. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17352269/),[μg] / [h·ml],66.85,184143,DB00122,Choline
,17352269,area under the concentration time-curve (AUC),"Even though the maximum observed concentration in the plasma (C(max) was greater for lipoplatin than for cisplatin, the area under the concentration time-curve (AUC) was less (6.5 microg/ml vs. 4.07 microg/ml and 66.85 microg/h/ml vs. 130.33 microg/h/ml, respectively).",Pharmacokinetics of liposomal cisplatin (lipoplatin) in combination with 5-FU in patients with advanced head and neck cancer: first results of a phase III study. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17352269/),[μg] / [h·ml],130.33,184144,DB00122,Choline
,30640475,concentration-time,"FP concentration-time profiles in the flow-past perfusate were similar irrespective of the medium used in the Dissolv It chamber (∼0.04-0.07%/min), but these were significantly lower than transfer of drug from air-to-perfusate in isolated perfused lungs (0.12%/min).","Use of PBPK Modeling To Evaluate the Performance of Dissolv It, a Biorelevant Dissolution Assay for Orally Inhaled Drug Products. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30640475/),[%] / [min],∼0,185378,DB00122,Choline
,30640475,transfer of,"FP concentration-time profiles in the flow-past perfusate were similar irrespective of the medium used in the Dissolv It chamber (∼0.04-0.07%/min), but these were significantly lower than transfer of drug from air-to-perfusate in isolated perfused lungs (0.12%/min).","Use of PBPK Modeling To Evaluate the Performance of Dissolv It, a Biorelevant Dissolution Assay for Orally Inhaled Drug Products. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30640475/),[%] / [min],0.12,185379,DB00122,Choline
,1733557,t1/2,"DP significantly increased the mean t1/2 for [3H]-ara-CTP from 102 to 136 min (P less than 0.01), but this effect was much less pronounced than that obtained for total tritium and the increase was quite variable (0-70%; median, 19%).",Modulation of the cellular pharmacokinetics of ara-CTP in human leukemic blasts by dipyridamole. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1733557/),min,102 to 136,186537,DB00122,Choline
,7137520,half-life,The half-life for intravenous theophylline in these asthmatics was 7.4 +/- 0.64.,Bioavailability of theophylline from three different tablets in asthmatic patients and their bronchodilating effects in combination with terbutaline inhalation. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7137520/),,7.4,191110,DB00122,Choline
,16012787,terminal half-life,"Perifosine was not metabolized and displayed slow elimination, with a terminal half-life of 137 (+/- 20) hours and an apparent volume of distribution of 11.3 l/kg.","Tumor and normal tissue pharmacokinetics of perifosine, an oral anti-cancer alkylphospholipid. ","t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/16012787/),h,137,192974,DB00122,Choline
,16012787,apparent volume of distribution,"Perifosine was not metabolized and displayed slow elimination, with a terminal half-life of 137 (+/- 20) hours and an apparent volume of distribution of 11.3 l/kg.","Tumor and normal tissue pharmacokinetics of perifosine, an oral anti-cancer alkylphospholipid. ",V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16012787/),[l] / [kg],11.3,192975,DB00122,Choline
,11923057,C(max),"The C(max) was not different between elephants and impala (20.3+/-7.9 vs. 14.4+/-6.8 nmol ml-1, respectively) but the t(max) was significantly longer for elephants (23.0+/-7.6 vs. 3.7+/-2.2 min).",Pharmacokinetics and effects of succinylcholine in African elephant (Loxodonta africana) and impala (Aepyceros melampus). ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11923057/),[nM] / [ml],20.3,194185,DB00122,Choline
,11923057,C(max),"The C(max) was not different between elephants and impala (20.3+/-7.9 vs. 14.4+/-6.8 nmol ml-1, respectively) but the t(max) was significantly longer for elephants (23.0+/-7.6 vs. 3.7+/-2.2 min).",Pharmacokinetics and effects of succinylcholine in African elephant (Loxodonta africana) and impala (Aepyceros melampus). ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11923057/),[nM] / [ml],14.4,194186,DB00122,Choline
,11923057,t(max),"The C(max) was not different between elephants and impala (20.3+/-7.9 vs. 14.4+/-6.8 nmol ml-1, respectively) but the t(max) was significantly longer for elephants (23.0+/-7.6 vs. 3.7+/-2.2 min).",Pharmacokinetics and effects of succinylcholine in African elephant (Loxodonta africana) and impala (Aepyceros melampus). ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11923057/),min,23.0,194187,DB00122,Choline
,11923057,t(max),"The C(max) was not different between elephants and impala (20.3+/-7.9 vs. 14.4+/-6.8 nmol ml-1, respectively) but the t(max) was significantly longer for elephants (23.0+/-7.6 vs. 3.7+/-2.2 min).",Pharmacokinetics and effects of succinylcholine in African elephant (Loxodonta africana) and impala (Aepyceros melampus). ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11923057/),min,3.7,194188,DB00122,Choline
,30054600,unbound fractions,The compounds' unbound fractions in plasma were 45-92%.,Human pharmacokinetics of ginkgo terpene lactones and impact of carboxylation in blood on their platelet-activating factor antagonistic activity. ,fu-Q46,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30054600/),%,45-92,196027,DB00122,Choline
>,30054600,Apparent oral bioavailability,"Apparent oral bioavailability of ginkgolides A and B was mostly >100%, while that of ginkgolides C and J was 6-15%.",Human pharmacokinetics of ginkgo terpene lactones and impact of carboxylation in blood on their platelet-activating factor antagonistic activity. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30054600/),%,100,196028,DB00122,Choline
,30054600,Apparent oral bioavailability,"Apparent oral bioavailability of ginkgolides A and B was mostly >100%, while that of ginkgolides C and J was 6-15%.",Human pharmacokinetics of ginkgo terpene lactones and impact of carboxylation in blood on their platelet-activating factor antagonistic activity. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30054600/),%,6-15,196029,DB00122,Choline
,30054600,Terminal half-lives,"Terminal half-lives of ginkgolides A, B, and C (4-7 h) after dosing ShuXueNing were shorter than their respective values (6-13 h) after dosing YinXing-TongZhi tablet.",Human pharmacokinetics of ginkgo terpene lactones and impact of carboxylation in blood on their platelet-activating factor antagonistic activity. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/30054600/),h,4-7,196030,DB00122,Choline
,30054600,Terminal half-lives,"Terminal half-lives of ginkgolides A, B, and C (4-7 h) after dosing ShuXueNing were shorter than their respective values (6-13 h) after dosing YinXing-TongZhi tablet.",Human pharmacokinetics of ginkgo terpene lactones and impact of carboxylation in blood on their platelet-activating factor antagonistic activity. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/30054600/),h,6-13,196031,DB00122,Choline
,30054600,Half-life,Half-life of bilobalide after dosing the tablet was around 5 h.,Human pharmacokinetics of ginkgo terpene lactones and impact of carboxylation in blood on their platelet-activating factor antagonistic activity. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30054600/),h,5,196032,DB00122,Choline
,28961737,Relative bioavailability,"Relative bioavailability was reduced (-74%, relative standard error 4.7%) during the first week of treatment of the monotherapy arm but only the first day of the shorter combination regimen.",Visceral leishmaniasis relapse hazard is linked to reduced miltefosine exposure in patients from Eastern Africa: a population pharmacokinetic/pharmacodynamic study. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/28961737/),%,-74,196987,DB00122,Choline
,28961737,Time to the relapse of infection,"Time to the relapse of infection could be described using a constant baseline hazard (baseline 1.8 relapses/year, relative standard error 72.7%).",Visceral leishmaniasis relapse hazard is linked to reduced miltefosine exposure in patients from Eastern Africa: a population pharmacokinetic/pharmacodynamic study. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/28961737/),,1.8,196988,DB00122,Choline
,28961737,Time > EC90,Miltefosine Time > EC90 improved the model significantly when added in a maximum effect function on the baseline hazard (half maximal effect with Time > EC90 6.97 days for monotherapy).,Visceral leishmaniasis relapse hazard is linked to reduced miltefosine exposure in patients from Eastern Africa: a population pharmacokinetic/pharmacodynamic study. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/28961737/),d,6.97,196989,DB00122,Choline
,7994371,Circulation half-lives,"Circulation half-lives following 50% isovolemic exchange-transfusion in rats were also similar, about 15-20 hours for either formation.","Efficacy, physical properties and pharmacokinetics of sterically-stabilized liposome-encapsulated hemoglobin. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7994371/),h,15-20,198347,DB00122,Choline
,20079628,t(max),"Pharmacokinetics after a single dose were median t(max)=8.0-24.2h, median t(1/2)=81.0-115.9h and mean(geo) CL/f=0.28-0.43mL/min/kg.",First-time-in-man and pharmacokinetic study of weekly oral perifosine in patients with solid tumours. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20079628/),h,8.0-24.2,198963,DB00122,Choline
,20079628,t(1/2),"Pharmacokinetics after a single dose were median t(max)=8.0-24.2h, median t(1/2)=81.0-115.9h and mean(geo) CL/f=0.28-0.43mL/min/kg.",First-time-in-man and pharmacokinetic study of weekly oral perifosine in patients with solid tumours. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20079628/),h,81.0-115.9,198964,DB00122,Choline
,20079628,CL/f,"Pharmacokinetics after a single dose were median t(max)=8.0-24.2h, median t(1/2)=81.0-115.9h and mean(geo) CL/f=0.28-0.43mL/min/kg.",First-time-in-man and pharmacokinetic study of weekly oral perifosine in patients with solid tumours. ,CLpo-Q27,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20079628/),[ml] / [kg·min],0.28-0.43,198965,DB00122,Choline
below,20079628,Urinary excretion,Urinary excretion was below 1%.,First-time-in-man and pharmacokinetic study of weekly oral perifosine in patients with solid tumours. ,ke-Q50,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20079628/),%,1,198966,DB00122,Choline
,20079628,half-life,"Based on its half-life of about 4days, a weekly regimen may be appropriate.",First-time-in-man and pharmacokinetic study of weekly oral perifosine in patients with solid tumours. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20079628/),d,4,198967,DB00122,Choline
,22585212,C(max),Exposure to miltefosine was lower in children than adults receiving 2.5 mg/kg/day: a C(max) of 18.8 μg/ml was reached by 90% of adults and 66.7% of children.,Optimal dosing of miltefosine in children and adults with visceral leishmaniasis. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22585212/),[μg] / [ml],18.8,202175,DB00122,Choline
,28521076,plasma concentration,The mean plasma concentration of perifosine was 27.5 ± 9.8 μM on day 15 and 27.3 ± 11.5 μM on day 29.,Phase I study of perifosine monotherapy in patients with recurrent or refractory neuroblastoma. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/28521076/),μM,27.5,204146,DB00122,Choline
,28521076,plasma concentration,The mean plasma concentration of perifosine was 27.5 ± 9.8 μM on day 15 and 27.3 ± 11.5 μM on day 29.,Phase I study of perifosine monotherapy in patients with recurrent or refractory neuroblastoma. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/28521076/),μM,27.3,204147,DB00122,Choline
,28521076,response rate (RR),The response rate (RR) in 18 patients evaluable according to modified International Neuroblastoma Response Criteria was 0%; the disease control rate (DCR) was 56%.,Phase I study of perifosine monotherapy in patients with recurrent or refractory neuroblastoma. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/28521076/),%,0,204148,DB00122,Choline
,28521076,progression-free survival (PFS),Median progression-free survival (PFS) was 122 days.,Phase I study of perifosine monotherapy in patients with recurrent or refractory neuroblastoma. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/28521076/),d,122,204149,DB00122,Choline
,28846866,lethal dose,"Acute oral toxicity test illustrated that choline chloride-glycerol (ChCl-GL, molar ratio 1:2) was non-toxic with the median lethal dose of 7733mg/kg.",The effect of deep eutectic solvent on the pharmacokinetics of salvianolic acid B in rats and its acute toxicity test. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/28846866/),[mg] / [kg],7733,205168,DB00122,Choline
,28846866,peak concentration (Cmax),"Compared to water, the pharmacokinetic parameters clarified that ChCl-GL (1:2) could promote the absorption of SAB, the peak concentration (Cmax) of 0.308±0.020mg/L was slightly higher than 0.277±0.024mg/L (SAB dissolved in water), and the peak time (Tmax) was significantly decreased from 30min (SAB dissolved in water) to 20min.",The effect of deep eutectic solvent on the pharmacokinetics of salvianolic acid B in rats and its acute toxicity test. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/28846866/),[mg] / [l],0.308,205169,DB00122,Choline
,28846866,peak concentration (Cmax),"Compared to water, the pharmacokinetic parameters clarified that ChCl-GL (1:2) could promote the absorption of SAB, the peak concentration (Cmax) of 0.308±0.020mg/L was slightly higher than 0.277±0.024mg/L (SAB dissolved in water), and the peak time (Tmax) was significantly decreased from 30min (SAB dissolved in water) to 20min.",The effect of deep eutectic solvent on the pharmacokinetics of salvianolic acid B in rats and its acute toxicity test. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/28846866/),[mg] / [l],0.277,205170,DB00122,Choline
,28846866,peak time (Tmax),"Compared to water, the pharmacokinetic parameters clarified that ChCl-GL (1:2) could promote the absorption of SAB, the peak concentration (Cmax) of 0.308±0.020mg/L was slightly higher than 0.277±0.024mg/L (SAB dissolved in water), and the peak time (Tmax) was significantly decreased from 30min (SAB dissolved in water) to 20min.",The effect of deep eutectic solvent on the pharmacokinetics of salvianolic acid B in rats and its acute toxicity test. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/28846866/),min,30,205171,DB00122,Choline
,28846866,peak time (Tmax),"Compared to water, the pharmacokinetic parameters clarified that ChCl-GL (1:2) could promote the absorption of SAB, the peak concentration (Cmax) of 0.308±0.020mg/L was slightly higher than 0.277±0.024mg/L (SAB dissolved in water), and the peak time (Tmax) was significantly decreased from 30min (SAB dissolved in water) to 20min.",The effect of deep eutectic solvent on the pharmacokinetics of salvianolic acid B in rats and its acute toxicity test. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/28846866/),min,20,205172,DB00122,Choline
,23443507,MTD,The MTD was determined to be UCN-01 65 mg/m(2) with perifosine 100 mg a day.,Phase I study of UCN-01 and perifosine in patients with relapsed and refractory acute leukemias and high-risk myelodysplastic syndrome. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23443507/),[mg] / [m],65,205505,DB00122,Choline
,34176411,oral bioavailability,"Lumefantrine (LMF) is first-line antimalarial drug, possesses activity against almost all human malarial parasites, but the in vivo activity of this molecule gets thwarted due to its low and inconsistent oral bioavailability (i.e. 4-12%) owing to poor biopharmaceutical attributes.",Improved biopharmaceutical attributes of lumefantrine using choline mimicking drug delivery system: preclinical investigation on NK-65 P.berghei murine model. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/34176411/),%,4-12,206301,DB00122,Choline
,34176411,selectivity indices,"Cytotoxicity studies on Hela and fibroblast cell lines demonstrated safety of LMF-PC with selectivity indices of 4395 and 5139, respectively.",Improved biopharmaceutical attributes of lumefantrine using choline mimicking drug delivery system: preclinical investigation on NK-65 P.berghei murine model. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/34176411/),,4395,206302,DB00122,Choline
,34176411,selectivity indices,"Cytotoxicity studies on Hela and fibroblast cell lines demonstrated safety of LMF-PC with selectivity indices of 4395 and 5139, respectively.",Improved biopharmaceutical attributes of lumefantrine using choline mimicking drug delivery system: preclinical investigation on NK-65 P.berghei murine model. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/34176411/),,5139,206303,DB00122,Choline
,11849919,t(1/2)(beta),"The core of deramciclane, carrying the ring label, was almost completely eliminated during 24 h, while the elimination of the side chain was very slow (t(1/2)(beta): 99 h).",Studies of the side chain cleavage of deramciclane in rats with radiolabelled compounds. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/11849919/),h,99,207057,DB00122,Choline
,30077712,IC50,"Both d-VAS and l-VAS were exhibited promising acetylcholinesterase (AChE) and butyrylcholinesterase (BChE) inhibitory activities, and the BChE inhibitory activity of d-VAS with IC50 of 0.03 ± 0.001 μM was significantly stronger than that of l-VAS with IC50 of 0.98 ± 0.19 μM.","Stereoselective glucuronidation metabolism, pharmacokinetics, anti-amnesic pharmacodynamics, and toxic properties of vasicine enantiomers in vitro and in vivo. ",IC50-Q10,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30077712/),μM,0.03,209813,DB00122,Choline
,30077712,IC50,"Both d-VAS and l-VAS were exhibited promising acetylcholinesterase (AChE) and butyrylcholinesterase (BChE) inhibitory activities, and the BChE inhibitory activity of d-VAS with IC50 of 0.03 ± 0.001 μM was significantly stronger than that of l-VAS with IC50 of 0.98 ± 0.19 μM.","Stereoselective glucuronidation metabolism, pharmacokinetics, anti-amnesic pharmacodynamics, and toxic properties of vasicine enantiomers in vitro and in vivo. ",IC50-Q10,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30077712/),μM,0.98,209814,DB00122,Choline
,30077712,LD50,"In addition, the LD50 value of d-VAS (282.51 mg·kg-1) was slight lower than l-VAS (319.75 mg·kg-1).","Stereoselective glucuronidation metabolism, pharmacokinetics, anti-amnesic pharmacodynamics, and toxic properties of vasicine enantiomers in vitro and in vivo. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30077712/),[mg] / [kg],282.51,209815,DB00122,Choline
,30077712,LD50,"In addition, the LD50 value of d-VAS (282.51 mg·kg-1) was slight lower than l-VAS (319.75 mg·kg-1).","Stereoselective glucuronidation metabolism, pharmacokinetics, anti-amnesic pharmacodynamics, and toxic properties of vasicine enantiomers in vitro and in vivo. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30077712/),[mg] / [kg],319.75,209816,DB00122,Choline
,30188978,plasma concentrations,"Miltefosine exposure at the start of treatment was increased, with higher median plasma concentrations on day 7 (5.88 versus 2.67 μg/mL).","Pharmacokinetics, Safety, and Efficacy of an Allometric Miltefosine Regimen for the Treatment of Visceral Leishmaniasis in Eastern African Children: An Open-label, Phase II Clinical Trial. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30188978/),[μg] / [ml],5.88,211718,DB00122,Choline
,30188978,plasma concentrations,"Miltefosine exposure at the start of treatment was increased, with higher median plasma concentrations on day 7 (5.88 versus 2.67 μg/mL).","Pharmacokinetics, Safety, and Efficacy of an Allometric Miltefosine Regimen for the Treatment of Visceral Leishmaniasis in Eastern African Children: An Open-label, Phase II Clinical Trial. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30188978/),[μg] / [ml],2.67,211719,DB00122,Choline
,33253802,incorporation efficiency (IE%),The optimized MTF-loaded NLCs exhibited mean particle size of 160.8 ± 5.3 nm with narrow PDI and high incorporation efficiency (IE%) of 96.17 ± 1.3%.,"Development, in vitro and in vivo evaluation of miltefosine loaded nanostructured lipid carriers for the treatment of Cutaneous Leishmaniasis. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/33253802/),%,96.17,216282,DB00122,Choline
,15756428,half-life,The half-life of Lipoplatin was 60-117 h depending on the dose.,Pharmacokinetics and adverse reactions of a new liposomal cisplatin (Lipoplatin): phase I study. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15756428/),h,60-117,217849,DB00122,Choline
,15756428,Urine excretion,Urine excretion reached about 40% of the infused dose in 3 days.,Pharmacokinetics and adverse reactions of a new liposomal cisplatin (Lipoplatin): phase I study. ,fe-Q44,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15756428/),%,40,217850,DB00122,Choline
,25183650,peak plasma concentration,The median peak plasma concentration of perifosine achieved at the MTD was approximately 8.3 µg/mL.,A phase I and pharmacokinetic study of oral perifosine with different loading schedules in patients with refractory neoplasms. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25183650/),[μg] / [ml],8.3,218796,DB00122,Choline
,16763096,half-life,"After DP-155 oral administration, indomethacin's half-life in the serum and the brain was 22 and 93 h, respectively, compared with 10 and 24 h following indomethacin oral administration.","A novel phospholipid derivative of indomethacin, DP-155 [mixture of 1-steroyl and 1-palmitoyl-2-{6-[1-(p-chlorobenzoyl)-5-methoxy-2-methyl-3-indolyl acetamido]hexanoyl}-sn-glycero-3-phosophatidyl [corrected] choline], shows superior safety and similar efficacy in reducing brain amyloid beta in an Alzheimer's disease model. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16763096/),h,22,218927,DB00122,Choline
,16763096,half-life,"After DP-155 oral administration, indomethacin's half-life in the serum and the brain was 22 and 93 h, respectively, compared with 10 and 24 h following indomethacin oral administration.","A novel phospholipid derivative of indomethacin, DP-155 [mixture of 1-steroyl and 1-palmitoyl-2-{6-[1-(p-chlorobenzoyl)-5-methoxy-2-methyl-3-indolyl acetamido]hexanoyl}-sn-glycero-3-phosophatidyl [corrected] choline], shows superior safety and similar efficacy in reducing brain amyloid beta in an Alzheimer's disease model. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16763096/),h,93,218928,DB00122,Choline
,16763096,half-life,"After DP-155 oral administration, indomethacin's half-life in the serum and the brain was 22 and 93 h, respectively, compared with 10 and 24 h following indomethacin oral administration.","A novel phospholipid derivative of indomethacin, DP-155 [mixture of 1-steroyl and 1-palmitoyl-2-{6-[1-(p-chlorobenzoyl)-5-methoxy-2-methyl-3-indolyl acetamido]hexanoyl}-sn-glycero-3-phosophatidyl [corrected] choline], shows superior safety and similar efficacy in reducing brain amyloid beta in an Alzheimer's disease model. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16763096/),h,10,218929,DB00122,Choline
,16763096,half-life,"After DP-155 oral administration, indomethacin's half-life in the serum and the brain was 22 and 93 h, respectively, compared with 10 and 24 h following indomethacin oral administration.","A novel phospholipid derivative of indomethacin, DP-155 [mixture of 1-steroyl and 1-palmitoyl-2-{6-[1-(p-chlorobenzoyl)-5-methoxy-2-methyl-3-indolyl acetamido]hexanoyl}-sn-glycero-3-phosophatidyl [corrected] choline], shows superior safety and similar efficacy in reducing brain amyloid beta in an Alzheimer's disease model. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16763096/),h,24,218930,DB00122,Choline
,9529308,T1/2,"After Exosurf inhalation, 99mTc-DTPA clearance at 10 min (T1/2; 35.6 +/- 8.7 min; n = 6) and 40 min (29.4 +/- 6.3 min; n = 4) was significantly prolonged compared with the matched baseline values (24.7 +/- 6.4 min, p < 0.0001; and 21.7 +/- 8.9 min, p = 0.01, respectively).",Effect of inhaled surfactant on pulmonary deposition and clearance of technetium-99m-DTPA radioaerosol. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9529308/),min,35.6,221495,DB00122,Choline
,9529308,T1/2,"After Exosurf inhalation, 99mTc-DTPA clearance at 10 min (T1/2; 35.6 +/- 8.7 min; n = 6) and 40 min (29.4 +/- 6.3 min; n = 4) was significantly prolonged compared with the matched baseline values (24.7 +/- 6.4 min, p < 0.0001; and 21.7 +/- 8.9 min, p = 0.01, respectively).",Effect of inhaled surfactant on pulmonary deposition and clearance of technetium-99m-DTPA radioaerosol. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9529308/),min,29.4,221496,DB00122,Choline
,9529308,T1/2,"After Exosurf inhalation, 99mTc-DTPA clearance at 10 min (T1/2; 35.6 +/- 8.7 min; n = 6) and 40 min (29.4 +/- 6.3 min; n = 4) was significantly prolonged compared with the matched baseline values (24.7 +/- 6.4 min, p < 0.0001; and 21.7 +/- 8.9 min, p = 0.01, respectively).",Effect of inhaled surfactant on pulmonary deposition and clearance of technetium-99m-DTPA radioaerosol. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9529308/),min,24.7,221497,DB00122,Choline
,9529308,T1/2,"After Exosurf inhalation, 99mTc-DTPA clearance at 10 min (T1/2; 35.6 +/- 8.7 min; n = 6) and 40 min (29.4 +/- 6.3 min; n = 4) was significantly prolonged compared with the matched baseline values (24.7 +/- 6.4 min, p < 0.0001; and 21.7 +/- 8.9 min, p = 0.01, respectively).",Effect of inhaled surfactant on pulmonary deposition and clearance of technetium-99m-DTPA radioaerosol. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9529308/),min,21.7,221498,DB00122,Choline
,11345644,Vmax,"The irinotecan carboxylesterase-converting enzyme in human plasma had a Vmax of 89.9 +/- 22.7 pmol/h per ml plasma and a Km of 207 +/- 56 microM (mean +/- SD, n = 3).",Human plasma carboxylesterase and butyrylcholinesterase enzyme activity: correlations with SN-38 pharmacokinetics during a prolonged infusion of irinotecan. ,Vmax-Q66,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11345644/),[pM] / [h·ml·plasma],89.9,223721,DB00122,Choline
,11345644,Km,"The irinotecan carboxylesterase-converting enzyme in human plasma had a Vmax of 89.9 +/- 22.7 pmol/h per ml plasma and a Km of 207 +/- 56 microM (mean +/- SD, n = 3).",Human plasma carboxylesterase and butyrylcholinesterase enzyme activity: correlations with SN-38 pharmacokinetics during a prolonged infusion of irinotecan. ,Km -Q1,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11345644/),μM,207,223722,DB00122,Choline
,11345644,specific activity,The mean value of the specific activity of this enzyme in 20 adult cancer patients was 10.08 +/- 2.96 pmol/h per ml plasma ranging from 5.43 to 15.39 pmol/h per ml.,Human plasma carboxylesterase and butyrylcholinesterase enzyme activity: correlations with SN-38 pharmacokinetics during a prolonged infusion of irinotecan. ,fm enzyme-Q5,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11345644/),[pM] / [h·ml],10.08,223723,DB00122,Choline
,11345644,specific activity,The mean value of the specific activity of this enzyme in 20 adult cancer patients was 10.08 +/- 2.96 pmol/h per ml plasma ranging from 5.43 to 15.39 pmol/h per ml.,Human plasma carboxylesterase and butyrylcholinesterase enzyme activity: correlations with SN-38 pharmacokinetics during a prolonged infusion of irinotecan. ,fm enzyme-Q5,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11345644/),[pM] / [h·ml],5.43 to 15.39,223724,DB00122,Choline
,29908755,mean residence time,"Pharmacokinetic studies of HuBChE in minipigs showed a mean residence time of 267 h, similar to the half-life of HuBChE in humans, suggesting a high degree of similarity between BChE from 2 sources.",Characterization of butyrylcholinesterase from porcine milk. ,MRT-Q53,[Article Link](https://pubmed.ncbi.nlm.nih.gov/29908755/),h,267,224064,DB00122,Choline
,9743409,onset time,"Inhibition of plasma cholinesterase activity (by 93% and 89%, respectively) increased the onset time of suxamethonium from a median of 40 s (range, 20-45 s) to 131 s (range, 114-166 s; P = 0.009) and of mivacurium from a median of 52 s (range, 40-59 s) to 105 s (range, 90-125 s; P = 0.009).",Inhibition of the enzymic degradation of suxamethonium and mivacurium increases the onset time of submaximal neuromuscular block. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9743409/),s,40,234253,DB00122,Choline
,9743409,onset time,"Inhibition of plasma cholinesterase activity (by 93% and 89%, respectively) increased the onset time of suxamethonium from a median of 40 s (range, 20-45 s) to 131 s (range, 114-166 s; P = 0.009) and of mivacurium from a median of 52 s (range, 40-59 s) to 105 s (range, 90-125 s; P = 0.009).",Inhibition of the enzymic degradation of suxamethonium and mivacurium increases the onset time of submaximal neuromuscular block. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9743409/),s,131,234254,DB00122,Choline
,9743409,onset time,"Inhibition of plasma cholinesterase activity (by 93% and 89%, respectively) increased the onset time of suxamethonium from a median of 40 s (range, 20-45 s) to 131 s (range, 114-166 s; P = 0.009) and of mivacurium from a median of 52 s (range, 40-59 s) to 105 s (range, 90-125 s; P = 0.009).",Inhibition of the enzymic degradation of suxamethonium and mivacurium increases the onset time of submaximal neuromuscular block. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9743409/),s,52,234255,DB00122,Choline
,9743409,onset time,"Inhibition of plasma cholinesterase activity (by 93% and 89%, respectively) increased the onset time of suxamethonium from a median of 40 s (range, 20-45 s) to 131 s (range, 114-166 s; P = 0.009) and of mivacurium from a median of 52 s (range, 40-59 s) to 105 s (range, 90-125 s; P = 0.009).",Inhibition of the enzymic degradation of suxamethonium and mivacurium increases the onset time of submaximal neuromuscular block. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9743409/),s,105,234256,DB00122,Choline
,16138006,minimum concentration at steady-state,Pharmacokinetic studies showed an average minimum concentration at steady-state of approximately 4059 ng/ml which correlated well with previous studies.,A phase II study of perifosine in androgen independent prostate cancer. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16138006/),[ng] / [ml],4059,234576,DB00122,Choline
,21056096,maximal concentration (Cmax),"Following sodium caprate pre-treatment, ropivacaine intrathecal maximal concentration (Cmax) was 1.6 times higher (78 ± 16 μg ml(-1) vs 129 ± 26 μg ml(-1), p<0.05) but the influence of the absorption enhancer was only effective the first 30 min following ropivacaine injection, as seen with the significantly increase of intrathecal AUC(0-30 min) (1629 ± 437 μg min ml(-1) vs 2477 ± 559 μg min ml(-1), p<0.05) resulting in a bioavailable fraction 130% higher 30 min after ropivavaine administration.",Ex vivo and in vivo diffusion of ropivacaine through spinal meninges: influence of absorption enhancers. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21056096/),[μg] / [ml],78,237657,DB00122,Choline
,21056096,maximal concentration (Cmax),"Following sodium caprate pre-treatment, ropivacaine intrathecal maximal concentration (Cmax) was 1.6 times higher (78 ± 16 μg ml(-1) vs 129 ± 26 μg ml(-1), p<0.05) but the influence of the absorption enhancer was only effective the first 30 min following ropivacaine injection, as seen with the significantly increase of intrathecal AUC(0-30 min) (1629 ± 437 μg min ml(-1) vs 2477 ± 559 μg min ml(-1), p<0.05) resulting in a bioavailable fraction 130% higher 30 min after ropivavaine administration.",Ex vivo and in vivo diffusion of ropivacaine through spinal meninges: influence of absorption enhancers. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21056096/),[μg] / [ml],129,237658,DB00122,Choline
,21056096,AUC(0-30 min),"Following sodium caprate pre-treatment, ropivacaine intrathecal maximal concentration (Cmax) was 1.6 times higher (78 ± 16 μg ml(-1) vs 129 ± 26 μg ml(-1), p<0.05) but the influence of the absorption enhancer was only effective the first 30 min following ropivacaine injection, as seen with the significantly increase of intrathecal AUC(0-30 min) (1629 ± 437 μg min ml(-1) vs 2477 ± 559 μg min ml(-1), p<0.05) resulting in a bioavailable fraction 130% higher 30 min after ropivavaine administration.",Ex vivo and in vivo diffusion of ropivacaine through spinal meninges: influence of absorption enhancers. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21056096/),[min·μg] / [ml],1629,237659,DB00122,Choline
,21056096,AUC(0-30 min),"Following sodium caprate pre-treatment, ropivacaine intrathecal maximal concentration (Cmax) was 1.6 times higher (78 ± 16 μg ml(-1) vs 129 ± 26 μg ml(-1), p<0.05) but the influence of the absorption enhancer was only effective the first 30 min following ropivacaine injection, as seen with the significantly increase of intrathecal AUC(0-30 min) (1629 ± 437 μg min ml(-1) vs 2477 ± 559 μg min ml(-1), p<0.05) resulting in a bioavailable fraction 130% higher 30 min after ropivavaine administration.",Ex vivo and in vivo diffusion of ropivacaine through spinal meninges: influence of absorption enhancers. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21056096/),[min·μg] / [ml],2477,237660,DB00122,Choline
,21056096,bioavailable fraction,"Following sodium caprate pre-treatment, ropivacaine intrathecal maximal concentration (Cmax) was 1.6 times higher (78 ± 16 μg ml(-1) vs 129 ± 26 μg ml(-1), p<0.05) but the influence of the absorption enhancer was only effective the first 30 min following ropivacaine injection, as seen with the significantly increase of intrathecal AUC(0-30 min) (1629 ± 437 μg min ml(-1) vs 2477 ± 559 μg min ml(-1), p<0.05) resulting in a bioavailable fraction 130% higher 30 min after ropivavaine administration.",Ex vivo and in vivo diffusion of ropivacaine through spinal meninges: influence of absorption enhancers. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21056096/),%,130,237661,DB00122,Choline
,25637066,zeta-potential,The polymeric micelles showed sizes ranging from 80 nm to 120 nm in hydrodynamic diameter and zeta-potentials from -6.4 mV to -2.4 mV by dynamic light scattering measurements.,Long circulating micelles of an amphiphilic random copolymer bearing cell outer membrane phosphorylcholine zwitterions. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25637066/),mv,-,237835,DB00122,Choline
,25637066,zeta-potential,The polymeric micelles showed sizes ranging from 80 nm to 120 nm in hydrodynamic diameter and zeta-potentials from -6.4 mV to -2.4 mV by dynamic light scattering measurements.,Long circulating micelles of an amphiphilic random copolymer bearing cell outer membrane phosphorylcholine zwitterions. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25637066/),mv,6.4,237836,DB00122,Choline
,25637066,zeta-potential,The polymeric micelles showed sizes ranging from 80 nm to 120 nm in hydrodynamic diameter and zeta-potentials from -6.4 mV to -2.4 mV by dynamic light scattering measurements.,Long circulating micelles of an amphiphilic random copolymer bearing cell outer membrane phosphorylcholine zwitterions. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25637066/),mv,2.4,237837,DB00122,Choline
,25637066,blood circulation half-life,The in vivo blood circulation half-life of the polymeric micelles following intravenous administration in New Zealand Rabbits was increased from 0.55 h to 90.5h.,Long circulating micelles of an amphiphilic random copolymer bearing cell outer membrane phosphorylcholine zwitterions. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25637066/),h,0.55,237838,DB00122,Choline
,25637066,blood circulation half-life,The in vivo blood circulation half-life of the polymeric micelles following intravenous administration in New Zealand Rabbits was increased from 0.55 h to 90.5h.,Long circulating micelles of an amphiphilic random copolymer bearing cell outer membrane phosphorylcholine zwitterions. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25637066/),h,90.5,237839,DB00122,Choline
,28290002,degrees,"For TMZ, the degrees of CSF drug penetration after intranasal and IV administration were 36 (32-57) and 22 (20-41)%, respectively.",Plasma and cerebrospinal fluid pharmacokinetics of select chemotherapeutic agents following intranasal delivery in a non-human primate model. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/28290002/),%,36,239223,DB00122,Choline
,28290002,degrees,"For TMZ, the degrees of CSF drug penetration after intranasal and IV administration were 36 (32-57) and 22 (20-41)%, respectively.",Plasma and cerebrospinal fluid pharmacokinetics of select chemotherapeutic agents following intranasal delivery in a non-human primate model. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/28290002/),%,22,239224,DB00122,Choline
,28290002,CSF drug penetration,"For TMZ, the degrees of CSF drug penetration after intranasal and IV administration were 36 (32-57) and 22 (20-41)%, respectively.",Plasma and cerebrospinal fluid pharmacokinetics of select chemotherapeutic agents following intranasal delivery in a non-human primate model. ,Papp-Q6,[Article Link](https://pubmed.ncbi.nlm.nih.gov/28290002/),%,36,239225,DB00122,Choline
,28290002,CSF drug penetration,"For TMZ, the degrees of CSF drug penetration after intranasal and IV administration were 36 (32-57) and 22 (20-41)%, respectively.",Plasma and cerebrospinal fluid pharmacokinetics of select chemotherapeutic agents following intranasal delivery in a non-human primate model. ,Papp-Q6,[Article Link](https://pubmed.ncbi.nlm.nih.gov/28290002/),%,22,239226,DB00122,Choline
,20819087,maximal plasma levels,"Rupatadine 40 mg reached maximal plasma levels of 15·1 ± 4·4 ng mL⁻¹)1 at 1 h and its metabolite, desloratadine, 5·2 ± 0·9 ng mL⁻¹)1 at 2 h.",Efficacy and tolerability of rupatadine at four times the recommended dose against histamine- and platelet-activating factor-induced flare responses and ex vivo platelet aggregation in healthy males. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20819087/),ml⁻¹)·ng,15·1,241088,DB00122,Choline
,20819087,maximal plasma levels,"Rupatadine 40 mg reached maximal plasma levels of 15·1 ± 4·4 ng mL⁻¹)1 at 1 h and its metabolite, desloratadine, 5·2 ± 0·9 ng mL⁻¹)1 at 2 h.",Efficacy and tolerability of rupatadine at four times the recommended dose against histamine- and platelet-activating factor-induced flare responses and ex vivo platelet aggregation in healthy males. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20819087/),ml⁻¹)·ng,5·2,241089,DB00122,Choline
,6651863,half-life,"Small solid liposomes made from distearoylphosphatidyl choline and cholesterol (molar ratio 2:1) showed significant stability in plasma, with a half-life of about 24 hr after intravenous injection in rats.",Cellular localization of stable solid liposomes in the liver of rats. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6651863/),h,24,242021,DB00122,Choline
,27084920,elimination t1/2,OlPC showed elimination t1/2 of ∼50 h and dose-proportional exposure.,Pharmacokinetics and pharmacodynamics of oleylphosphocholine in a hamster model of visceral leishmaniasis. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/27084920/),h,∼50,248399,DB00122,Choline
,15980324,t(1/2),Pharmacokinetic studies in rhesus monkeys indicated that D-FDOC has a t(1/2) of 2.1 h in plasma and an oral bioavailability of 38%.,"Pharmacology and pharmacokinetics of the antiviral agent beta-D-2',3'-dideoxy-3'-oxa-5-fluorocytidine in cells and rhesus monkeys. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15980324/),h,2.1,251237,DB00122,Choline
,15980324,oral bioavailability,Pharmacokinetic studies in rhesus monkeys indicated that D-FDOC has a t(1/2) of 2.1 h in plasma and an oral bioavailability of 38%.,"Pharmacology and pharmacokinetics of the antiviral agent beta-D-2',3'-dideoxy-3'-oxa-5-fluorocytidine in cells and rhesus monkeys. ",F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15980324/),%,38,251238,DB00122,Choline
,8122251,apparent volume of distribution,"The pharmacokinetic parameters were (SCh 1, n = 8 and 2 mg/kg, n = 6): apparent volume of distribution (16.4 +/- 14.7 and 5.6 +/- 6.8 ml/kg, mean +/- S.D.), total body clearance (40.5 +/- 38.7 and 15.0 +/- 14.8 liter/min), area under the plasma concentration-time curve (124.3 +/- 163.2 and 695.3 +/- 1008.9 min.micrograms/ml), and elimination half-life (16.6 +/- 4.8 and 11.7 +/- 4.5 sec).",Pharmacokinetics of succinylcholine in man. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8122251/),[ml] / [kg],16.4,258948,DB00122,Choline
,8122251,apparent volume of distribution,"The pharmacokinetic parameters were (SCh 1, n = 8 and 2 mg/kg, n = 6): apparent volume of distribution (16.4 +/- 14.7 and 5.6 +/- 6.8 ml/kg, mean +/- S.D.), total body clearance (40.5 +/- 38.7 and 15.0 +/- 14.8 liter/min), area under the plasma concentration-time curve (124.3 +/- 163.2 and 695.3 +/- 1008.9 min.micrograms/ml), and elimination half-life (16.6 +/- 4.8 and 11.7 +/- 4.5 sec).",Pharmacokinetics of succinylcholine in man. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8122251/),[ml] / [kg],5.6,258949,DB00122,Choline
,8122251,total body clearance,"The pharmacokinetic parameters were (SCh 1, n = 8 and 2 mg/kg, n = 6): apparent volume of distribution (16.4 +/- 14.7 and 5.6 +/- 6.8 ml/kg, mean +/- S.D.), total body clearance (40.5 +/- 38.7 and 15.0 +/- 14.8 liter/min), area under the plasma concentration-time curve (124.3 +/- 163.2 and 695.3 +/- 1008.9 min.micrograms/ml), and elimination half-life (16.6 +/- 4.8 and 11.7 +/- 4.5 sec).",Pharmacokinetics of succinylcholine in man. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8122251/),[l] / [min],40.5,258950,DB00122,Choline
,8122251,total body clearance,"The pharmacokinetic parameters were (SCh 1, n = 8 and 2 mg/kg, n = 6): apparent volume of distribution (16.4 +/- 14.7 and 5.6 +/- 6.8 ml/kg, mean +/- S.D.), total body clearance (40.5 +/- 38.7 and 15.0 +/- 14.8 liter/min), area under the plasma concentration-time curve (124.3 +/- 163.2 and 695.3 +/- 1008.9 min.micrograms/ml), and elimination half-life (16.6 +/- 4.8 and 11.7 +/- 4.5 sec).",Pharmacokinetics of succinylcholine in man. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8122251/),[l] / [min],15.0,258951,DB00122,Choline
,8122251,area under the plasma concentration-time curve,"The pharmacokinetic parameters were (SCh 1, n = 8 and 2 mg/kg, n = 6): apparent volume of distribution (16.4 +/- 14.7 and 5.6 +/- 6.8 ml/kg, mean +/- S.D.), total body clearance (40.5 +/- 38.7 and 15.0 +/- 14.8 liter/min), area under the plasma concentration-time curve (124.3 +/- 163.2 and 695.3 +/- 1008.9 min.micrograms/ml), and elimination half-life (16.6 +/- 4.8 and 11.7 +/- 4.5 sec).",Pharmacokinetics of succinylcholine in man. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8122251/),[min·μg] / [ml],124.3,258952,DB00122,Choline
,8122251,area under the plasma concentration-time curve,"The pharmacokinetic parameters were (SCh 1, n = 8 and 2 mg/kg, n = 6): apparent volume of distribution (16.4 +/- 14.7 and 5.6 +/- 6.8 ml/kg, mean +/- S.D.), total body clearance (40.5 +/- 38.7 and 15.0 +/- 14.8 liter/min), area under the plasma concentration-time curve (124.3 +/- 163.2 and 695.3 +/- 1008.9 min.micrograms/ml), and elimination half-life (16.6 +/- 4.8 and 11.7 +/- 4.5 sec).",Pharmacokinetics of succinylcholine in man. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8122251/),[min·μg] / [ml],695.3,258953,DB00122,Choline
,8122251,elimination half-life,"The pharmacokinetic parameters were (SCh 1, n = 8 and 2 mg/kg, n = 6): apparent volume of distribution (16.4 +/- 14.7 and 5.6 +/- 6.8 ml/kg, mean +/- S.D.), total body clearance (40.5 +/- 38.7 and 15.0 +/- 14.8 liter/min), area under the plasma concentration-time curve (124.3 +/- 163.2 and 695.3 +/- 1008.9 min.micrograms/ml), and elimination half-life (16.6 +/- 4.8 and 11.7 +/- 4.5 sec).",Pharmacokinetics of succinylcholine in man. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/8122251/),s,16.6,258954,DB00122,Choline
,8122251,elimination half-life,"The pharmacokinetic parameters were (SCh 1, n = 8 and 2 mg/kg, n = 6): apparent volume of distribution (16.4 +/- 14.7 and 5.6 +/- 6.8 ml/kg, mean +/- S.D.), total body clearance (40.5 +/- 38.7 and 15.0 +/- 14.8 liter/min), area under the plasma concentration-time curve (124.3 +/- 163.2 and 695.3 +/- 1008.9 min.micrograms/ml), and elimination half-life (16.6 +/- 4.8 and 11.7 +/- 4.5 sec).",Pharmacokinetics of succinylcholine in man. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/8122251/),s,11.7,258955,DB00122,Choline
,1743246,I50,The effect of RP 48740 displayed a sigmoidal relation to the plasma drug concentration; I50 2.3 (0.3) mg.l-1.,Inhibition of ex-vivo PAF-induced platelet aggregation by the PAF-antagonist RP 48740: relationship to plasma concentrations in healthy volunteers. ,IC50-Q10,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1743246/),[mg] / [l],2.3,265131,DB00122,Choline
,22851635,radioactive half-life,"However, the 20.4-min radioactive half-life of (11)C-AA and challenges of routinely synthesizing (11)C fatty acids limit their translational utility as PET biomarkers.",The synthesis and in vivo pharmacokinetics of fluorinated arachidonic acid: implications for imaging neuroinflammation. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22851635/),min,20.4,267507,DB00122,Choline
,22851635,radioactive half-life,"As a first step to develop a clinically useful (18)F-fluoroarachidonic acid ((18)F-FAA) with a long radioactive half-life of 109.8 min, we report here a high-yield stereoselective synthetic method of nonradioactive 20-(19)F-FAA.",The synthesis and in vivo pharmacokinetics of fluorinated arachidonic acid: implications for imaging neuroinflammation. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22851635/),min,109.8,267508,DB00122,Choline
,33606068,AUCs,"The AUCs in the in vitro brain cell culture after 14-day repeated dosing of nominal concentration equal to 1.25 and 2.5 µM amiodarone were 1.00 and 1.99 µg*h/mL, respectively.",Prediction of the dose range for adverse neurological effects of amiodarone in patients from an in vitro toxicity test by in vitro-in vivo extrapolation. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/33606068/),[h·μg] / [ml],1.00,267793,DB00122,Choline
,33606068,AUCs,"The AUCs in the in vitro brain cell culture after 14-day repeated dosing of nominal concentration equal to 1.25 and 2.5 µM amiodarone were 1.00 and 1.99 µg*h/mL, respectively.",Prediction of the dose range for adverse neurological effects of amiodarone in patients from an in vitro toxicity test by in vitro-in vivo extrapolation. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/33606068/),[h·μg] / [ml],1.99,267794,DB00122,Choline
,33606068,bioavailability factor,The BMDU was 385.4 mg for intravenous converted to 593 mg for oral application using the bioavailability factor of 0.65 as reported in the literature.,Prediction of the dose range for adverse neurological effects of amiodarone in patients from an in vitro toxicity test by in vitro-in vivo extrapolation. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/33606068/),,0.65,267795,DB00122,Choline
,16678871,terminal elimination half-life,The terminal elimination half-life was 14.8 days.,Quantification of the response to miltefosine treatment for visceral leishmaniasis by QT-NASBA. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/16678871/),d,14.8,268062,DB00122,Choline
,20519143,EC50,Oral administration of AM803 (1 mg/kg) resulted in sustained inhibition of ex vivo ionophore-challenged whole blood LTB4 biosynthesis with >90% inhibition for up to 12 h and an EC50 of approximately 7 nM.,"Pharmacology of AM803, a novel selective five-lipoxygenase-activating protein (FLAP) inhibitor in rodent models of acute inflammation. ",EC50-Q16,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20519143/),nM,7,269260,DB00122,Choline
,20519143,ED50s,"When rat lungs were challenged in vivo with calcium-ionophore, AM803 inhibited LTB4 and cysteinyl leukotriene (CysLT) production with ED50s of 0.12 mg/kg and 0.37 mg/kg, respectively.","Pharmacology of AM803, a novel selective five-lipoxygenase-activating protein (FLAP) inhibitor in rodent models of acute inflammation. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20519143/),[mg] / [kg],0.12,269261,DB00122,Choline
,20519143,ED50s,"When rat lungs were challenged in vivo with calcium-ionophore, AM803 inhibited LTB4 and cysteinyl leukotriene (CysLT) production with ED50s of 0.12 mg/kg and 0.37 mg/kg, respectively.","Pharmacology of AM803, a novel selective five-lipoxygenase-activating protein (FLAP) inhibitor in rodent models of acute inflammation. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20519143/),[mg] / [kg],0.37,269262,DB00122,Choline
,28264602,oral bioavailability,The drug suffers from poor oral bioavailability (50%) due to its first pass effect and a short elimination half-life of 4 h; resulting in its frequent administration.,Enhancement of the bioavailability of an antihypertensive drug by transdermal protransfersomal system: formulation and in vivo study. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/28264602/),%,50,272083,DB00122,Choline
,28264602,elimination half-life,The drug suffers from poor oral bioavailability (50%) due to its first pass effect and a short elimination half-life of 4 h; resulting in its frequent administration.,Enhancement of the bioavailability of an antihypertensive drug by transdermal protransfersomal system: formulation and in vivo study. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/28264602/),h,4,272084,DB00122,Choline
,28264602,permeation rate,Optimized protransfersomal system had excellent permeation rate through shaved rat skin (780.69 μg/cm2/h) and showed six times increase in relative bioavailability with prolonged plasma profile up to 72 h.,Enhancement of the bioavailability of an antihypertensive drug by transdermal protransfersomal system: formulation and in vivo study. ,Papp-Q6,[Article Link](https://pubmed.ncbi.nlm.nih.gov/28264602/),[μg] / [cm2·h],780.69,272085,DB00122,Choline
